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Epidemiological studies have suggested that at least 15% of colorectal cancers
occur in dominantly inherited patterns. Hereditary Nonpolyposis Colorectal
Cancer (HNPCC) is an autosomal dominant disorder characterised by the early
onset of colorectal cancer and is linked to germline mutations in any one of
several genes involved in DNA mismatch repair. Defects in MSH2 account for at
least 50% of cases of HNPCC with loss of DNA mismatch repair resulting in
microsatellite instability which occurs in the majority of tumours from patients
with HNPCC and also in approximately 13-17% of sporadic colorectal cancers.
Hence, the normal function of MSH2 in repairing incorrectly paired nucleotides
following DNA replication is essential to the maintenance of genomic integrity
and prevention of tumourigenesis. To investigate further the role of MSH2 in
these processes mice carrying a null mutation in the MSH2 gene were studied.
Several different endpoints associated with carcinogenesis were addressed
including apoptosis, mutation frequency, and genomic instability.
Tumour cells which lack DNA mismatch repair are resistant to the cytotoxic
effects of DNA methylating agents and Cisplatin. To address whether this
resistance is mediated through loss of an MN//2-dependent apoptotic pathway,
the apoptotic response of the murine small intestine to DNA methylating agents
and Cisplatin was studied. MSH2 was found to play a significant role in the
initiation of apoptosis in vivo. The immediate apoptotic response to these agents
was />53-dependent in the first 24 hours, however a smaller /^-independent
apoptotic response was observed beyond this point. Mice doubly null for both
MSH2 and p53 revealed that this delayed /j53-independent response was entirely
MST/2-dependent. These results demonstrate the existence of a pathway to
apoptosis following DNA methylation which is dependent upon both MSH2 and
p53.
The DNA repair enzyme f/-Alkylguanine-DNA-alkyltransferase (AGT), which
removes potentially mutagenic methyl groups from guanine residues, appeared
to play no significant role in modulating the MS7J2-dependent apoptotic
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response of intestinal cells to methylating agents or Cisplatin. (?6-BenzyIguanine,
a competitive inhibitor of AGT, prevented the metabolic activation of
Dacarbazine probably through the inhibition of cytochrome P450 enzymes. This
novel finding has adverse implications towards the potential clinical use of O6-
Benzylguanine.
The consequences of MSH2 loss upon in vivo mutation frequency, either
through loss of an apoptotic pathway or through failed DNA repair was
investigated. A six-fold elevation in the spontaneous mutation frequency at the
Dlb-1 locus within cells of the intestinal epithelium was observed in MSH2 null
mice compared to wild-type controls. MST/^-deficiency also resulted in 13.8 and
5.0-fold elevations in mutation frequency following exposure to the methylating
agents Temozolomide and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)
respectively. In contrast, a minor 1.7-fold increase in mutation frequency was
observed for Cisplatin. These results highlight the capacity for MA/f2-deficiency
to serve as a potent driving force during the multi-step evolution of colon
tumours, especially following exposure to methylating type DNA damage.
Genomic instability is an integral component of colorectal neoplasia and can
occur through mismatch repair deficiency and instability at the nucleotide
sequence level. Alternatively chromosomal instability and the development of
aneuploidy may occur which are strongly associated with p53 deficiency. The
contribution of these two forms of instability in murine tumourigenesis was
addressed in an inter-cross of MSH2 null and p53 null mice. MSH2 -/- p53 -/-
mice were viable but rapidly succumbed to tumours. Combined ablation of
MSH2 and p53 in mice accelerated tumourigenesis significantly earlier than
deficiency of MSH2 or p53 alone. Furthermore, absence of MSH2 function
greatly accelerated the rate of tumour development in p53 heterozygote mice.
Analysis of the tumours, arising in mice segregating for MSH2 and p53
deficiency, by flow cytometry and comparative genomic hybridisation suggested
that MSH2-driven genomic instability was the predominant pathway.
The data presented in this thesis demonstrate that MSH2 plays a pivotal role in
determining both the apoptotic response and mutation frequency of the murine
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intestine to methylating DNA damage and suggests that the consequences of






Neoplasia is the abnormal proliferation of cells within a tissue. Cancer is a malignant
form of neoplasia characterised by its ability to invade surrounding structures and
spread throughout the body in the form of metastasis. In the United Kingdom, over
250 000 new cases of cancer are recorded each year, and from such a statistic it is
estimated that 1 in 3 people are at risk of developing cancer at sometime during their
life. Over 30 000 new cases of colorectal cancer are diagnosed each year which have a
5 year survival of only 37% (Cancer Research Campaign, 1997). Despite lifestyle
changes and intensive research, neither the incidence, nor the 5 year survival, has
altered materially over the past 20 years. Research into the pathogenesis of this
disease is needed to understand the critical events in its evolution. Armed with this
knowledge measures to decrease its incidence and increase the effectiveness of
therapy can be implemented
COLORECTAL CANCER
Carcinogenesis within the colon is a multi-step process which involves the transition
from normal epithelium sequentially through a hyperproliferative state, then
adenomatous changes with increasing dysplasia, and finally frank malignancy with
metastasis. This sequence is known as the adenoma-carcinoma sequence and the
evolution of each well defined morphological stage is associated with progressive
genetic changes (Fearon & Vogelstein, 1990) (Figure A). The transition from normal
epithelium to adenoma is very strongly associated with loss of Adenomatous
Polyposis Coli (APC) gene product function (Groden et al., 1991). Mutations in a
number of genes including K-ras, Deleted in Colorectal Cancer (DCC), and DPC4
may then occur in one of these benign tumour cells leading to further clonal expansion
(Vogelstein & Kinzler, 1993; MacGrogan et al., 1997). Finally, mutations in the p53
gene are thought to drive the change from benign tumourigenesis to malignancy. This
process of sequential mutations can be accelerated by the phenomenon of genomic
instability which occurs following mutations in one of the DNA mismatch repair
enzymes, for example MSH2. Our understanding of the adenoma-carcinoma sequence
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GenomicInstab lity(Mi m tchR pairD ficien y) ACCELERATION
has been greatly facilitated through the study of inherited forms of colorectal cancer
and murine models.
Familial Adenomatous Polyposis Coli
Familial Adenomatous Polyposis Coli (FAP) is a dominantly inherited syndrome in
which affected individuals are predisposed to develop numerous intestinal adenomas.
It accounts for less than 1% of colorectal cancer with an incidence of 1 in 7000
(Kinzler & Vogelstein, 1996). Patients with FAP have many hundreds to thousands of
polyps scattered throughout the gastrointestinal tract but mainly located in the colon.
They appear between the ages of 10 and 35 and without surgical treatment, the
presentation of malignant tumour invariably follows leaving FAP patients with a mean
life expectancy of 40 years (Bussey, 1978). In addition to the colonic polyposis some
individuals also develop extra-colonic manifestations including multiple osteomas,
exostoses of the skeleton, desmoid tumours, and congenital hypertrophic retinal
pigment epithelium (CHRPE) (Gorlin & Chaudry, 1960; Lewis, et al., 1984).
Mutations in the Adenomatous Polyposis Coli (.APC) gene are responsible for FAP.
Individuals with FAP carry a germline mutation in one copy of APC (Groden et al.,
1991; Kinzler et al., 1991). Somatic mutations in the remaining allele lead to defective
APC function and the development of adenomas. Inactivation of APC has also been
shown to occur in the majority of sporadic colorectal adenomas and carcinomas
(Cottrell et al., 1992). Most mutations identified create premature stop codons, 60%
of which are in exon 15 and result in truncation of the APC protein (Nagase &
Nakamura, 1993; Polakis, 1995). Furthermore, the exact location of the mutation
within the APC gene can determine the number of polyps and whether extra-colonic
features are present (Cunningham & Dunlop, 1996).
At a biochemical level APC protein binds P-catenin through two binding repeat motifs
located in the central third of the protein, promoting P-catenin destruction (Rubinfeld
et al., 1993; Iylas & Tomlinson, 1997). The APC/p-catenin complex regulates cell
adhesion and migration through its interaction with the cell surface molecule E-
cadherin and its contol over microtubule formation (Kemler, 1993; Gumbiner, 1995;
Smith et al., 1994; Munemitsu et al., 1994). Virtually all mutant APC proteins lack at
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least one type of (3-catenin repeat, and fail to bind P-catenin resulting in a rise of free
P-catenin within the cell (Rubinfeld et al., 1996; Peifer, 1997). An increase of free P-
catenin within the cell activates transcription factors of the T-cell factor-lymphoid
enhancer family (Tcf-Lef), modifying gene expression. The genes activated are
thought to promote cell proliferation and antagonise apoptosis (Peifer, 1997).
Hereditary Nonpolyposis Colorectal Cancer
Approximately 15% of all colorectal cancers occur in dominantly inherited patterns
(Cannon-Albright et al., 1988). Hereditary Nonpolyposis Colorectal Cancer
(HNPCC) accounts for about 5% of all colorectal cancers with estimates of the
incidence of HNPCC varying from 1 in 200 to 1 in 500, making it one of the
commonest inherited diseases (Kinzler & Vogelstein, 1996). This figure is likely to be
an underestimate as the International Collaborative Group on HNPCC has set
stringent criteria (primarily for research purposes) for the diagnosis of HNPCC
(Vasen et al., 1991). The criteria are as follows: (1) three or more relatives with
histologically proven colorectal cancer, one of whom is a first degree relative of the
other two; (2) colorectal cancer involving at least two generations; and (3) at least
one family member affected before the age of 50 years. In a clinical setting HNPCC is
characterised by an autosomal dominant mode of inheritance with high penetrance,
and the development of colorectal cancers which show a preponderance for the
proximal colon (before the splenic flexure), in the absence of multiple polyps (Lynch
et al., 1993; Thibodeau et al., 1993). In contrast to sporadic colorectal cancer which
affects patients with an average age of 67, HNPCC patients with colorectal cancer
have a mean age of 42 years at diagnosis (Kinzler & Vogelstein, 1996). Colon
carcinomas arising in HNPCC patients often show different clinical and pathological
features from non-HNPCC related cancers, tending to be larger with a near-diploid
DNA content, confer a more favourable prognosis, display microsatellite instability
and demonstrate a lower frequency of p53 protein immunoreactivity (Kouri et al.,
1990; Lothe et al., 1993). Histologically, the HNPCC colon cancers include higher
proportions of mucinous, poorly differentiated carcinomas and tend to show more
prominent lymphocytic infiltration (Kim et al., 1994). There is a tendency for HNPCC
13
individuals to develop multiple colorectal cancers. Indeed, if patients do not receive a
subtotal colectomy following initial diagnosis, 40% develop a second carcinoma
within 10 years (Lynch et al., 1996). Individuals with HNPCC may develop colorectal
cancer alone (Lynch type I syndrome) or may develop additional tumours throughout
the body, particularly cancers of the endometrium (the most prevalent extra-colonic
tumour), ovary, stomach, upper urinary tract, pancreas, small bowel and skin (Lynch
type II syndrome) (Lynch et al., 1996). The Muir-Torre syndrome is considered to be
a subset of HNPCC and is characterised by the association of colon cancers and skin
tumours, especially sebaceous gland neoplasms and keratoacanthomas (Cohen et al.,
1991; Kolodner et al., 1994).
DNA mismatch repair and HNPCC
Insights into the cause of HNPCC came from three related areas of research. First,
using linkage analysis to study large kindreds affected by the disease some of the
genes responsible were found to map to either chromosome 2pl6 or 3p21 and be
transmitted by a pattern of autosomal dominant inheritance (Peltomaki et al., 1993a;
Lindblom et al., 1993). Second, analysis of oncosuppressor gene changes in tumours
from these patients, by loss of heterozygosity at numerous microsatellite loci
throughout the genome, showed regions of expanded microsatellites rather than
evidence of loss as predicted [microsatellites are repetitive DNA sequences where the
unit of repetition is often short, such as mono-, di-, or tri- nucleotide groups and these
are scattered throughout the genome e.g. CACA(CA)n...] (Aaltonen et al., 1993;
Thibodeau et al., 1993). Finally, similar patterns of change in microsatellites had
already been observed in bacteria harbouring mutations in the bacterial DNA
mismatch repair enzymes mutS and mutL (Levinson & Gutman, 1987). Tying all these
lines of investigation together, it emerged that the human homologues of bacterial
mutS and mutL, called hMSH2 and hMLHl, were located on chromosomes 2pl6 and
3p21 respectively, and were found to be mutated in different HNPCC kindreds (Leach
et al., 1993; Papadopoulos et al., 1994).
The DNA mismatch repair (MMR) pathway is essential for the correct maintenance of
genetic material (Fishel & Kolodner, 1995). It functions to remove misincorporated
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single nucleotide bases following DNA replication or recombination, and also small
loops of DNA which arise through slippage of the DNA polymerase on the template
strand of DNA during DNA replication. This phenomenon of slippage is more likely
to occur at sites of repetition of short units of DNA sequence, such as microsatellites.
In addition, the DNA mismatch repair system has been shown to have an important
role in the cytotoxicity of alkylating mutagens/carcinogens through the lethal
processing of mispaired methylated guanine residues (Branch et al., 1993; Karran &
Bignami, 1994).
The MMR pathway consists of a number of enzymes beginning with a heterodimer
(known as mutSa) of HMSH2 protein and G/T mismatch-binding protein
(GTBP/pi60) that is capable of recognising and binding to DNA mismatches
(Drummond et al., 1995). Another mutS homologue, hMSH2 may bind hMSH2
replacing GTBP, forming a heterodimer (called mutS/3), which increases the specificity
for loops of nucleotides (Risinger et al., 1996; Palombo et al., 1996). However, the
majority of hMSH2 is bound to GTBP. Subsequently, a second heterodimer consisting
of hMLHl and hPMS2 proteins (mutL) is recruited and binds to the hMSH2/GTBP
dimer forming a large complex (Kolodner, 1995). Finally, the DNA mismatch is
repaired by excision of the DNA strand containing the mismatch or modified base and
synthesis of a correct complementary DNA strand through the actions of undefined
helicase, nuclease, polymerase and ligase enzymes which use the intact DNA strand as
a template. The role of hPMSl in this process is unknown. The specific components
of the MMR are shown in Figure B.
HNPCC affected individuals are heterozygous for a germline mutation in one of at
least four DNA mismatch repair enzymes hMSH2, hMLHl, hPMSl, hPMS2 which
are found on chromosomes 2p, 3p, 2q, and 7p respectively (Kinzler & Vogelstein,
1996). Mutations in hMSH2 and hMLHl together account for approximately 95% of
germline mutations reported (Wijnen et al., 1998). However, only in one quarter of
HNPCC cases can such mutations be identified (Wijnen et al., 1998). Seventy percent
of the germline mutations identified produce truncated forms of the protein with loss
of function, with the remainder being missense mutations (Kinzler & Vogelstein,
1996). In addition, mutations in GTBP have been identified in cell lines with
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Figure B
Components of the DNA mismatch repair system and their mechanism of action.
a) Double-stranded DNA containing a single base mismatch or a loop of nucleotides
due to strand slippage.
b) Mismatch recognised by a heterodimer of hMSH2 and GTBP proteins with
recruitment ofhMLHl and hPMS2 proteins.
c) Removal of the mismatch is effected by the excision of the altered DNA single
strand by the action of undefined helicase and nuclease enzymes.
d) Repair is completed by synthesis of a new DNA strand complementary to the intact















microsatellite instability and a germline mutation of GTBP has been identified in a
single HNPCC pedigree (Papadopoulos et al., 1995; Miyaki et al., 1997).
Tumour cells from HNPCC individuals harbour mutations or alterations in both alleles
of a mismatch repair gene, with inheritance of one mutated allele and loss of function
of the second allele occurring through somatic mutation or allele loss leading to
reduction to homozygosity. Thus, MMR genes behave as true tumour suppressor
genes in keeping with Knudson's two hit hypothesis (Knudson, 1985). This loss of
post-replicative DNA mismatch repair increases mutation rates 100 to 600 fold above
normal levels (Shibata et al., 1993; Bhattacharyya et al., 1994; Eshleman et al.,
1995). Such tumours may be described as possessing a "mutator phenotype" in the
absence of effective DNA mismatch repair. This mutator phenotype has two
consequences. First, the replication error phenotype (RER+) described above is
acquired leading to the appearance of microsatellite instabilty which were it restricted
to nonexonic sequences would be in itself harmless to the cell.. Second, and more
ominously, there is a susceptibility to rapid accumulation of mutations in many
different genes including growth controlling genes anywhere in the genome, hence
explaining the accelerated progression through the multi-step adenoma to carcinoma
pathway. A prominent example is mutation in the TGF|3II receptor gene which
contains a stretch of repetitive dinucleotides within one of the exons that acts as a
target for deficient DNA mismatch repair (Markowitz et al., 1995). It is also possible
that the RER phenotype may produce mutations in the other components of the
DNA repair systems accelerating tumourigenesis even further (Perucho, 1996).
Sporadic colorectal cancer and microsatellite instability
By the age of 70 years about half the population in industrialised nations have a
benign adenoma in their colon but only one in ten develop an invasive carcinoma
(Kinzler & Vogelstein, 1996). Such colon cancers arising in patients with a negative
family history for colon cancer are termed "sporadic" carcinomas. Microsatellite
instability can be shown in around 15% of all sporadic colorectal carcinomas
(Aaltonen et al., 1993; Lothe et al., 1993). These sporadic colon cancers with
microsatellite instability share similar characteristics to HNPCC tumours, tending to
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be larger, located in the proximal colon, diploid, and poorly differentiated or
mucinous (Chung & Rustgi, 1995). However, the role of the common DNA mismatch
repair enzymes in their pathogenesis is less clear (Eshleman & Markowitz, 1996).
Approximately 60% of sporadic tumours harbour mutations in the same DNA
mismatch repair genes that cause HNPCC, whereas in other cancers no mutations in
MMR genes can be identified (Liu et al., 1995; Eshleman & Markowitz, 1996).
However, mutations have been detected in other components of the mismatch repair
system including GTBP, MSH3, and the proofreading domain of polymerase 8 (da
Costa et al., 1995; Malkhosyan et al., 1996). It is possible that uncharacterised DNA
repair genes may be mutated or that inactivation of known MMR genes may involve
subtle intronic lesions or transcriptional pathways (Bubb et al., 1996). A comparison
of the relative importance of each DNA mismatch repair enzyme to both HNPCC and
sporadic colorectal carcinomas is shown in Table 1.
Other cancers with microsatellite instability
Cancers arising in other tissues of the body distinct from the colon have also been
shown to have microsatellite instability and show a RER phenotype (Eshleman &
Markowitz, 1995). For example, endometrial carcinomas arising in both HNPCC
patients and sporadic cases display microsatellite instability in 75% and 17% of
cancers respectively (Risinger et al., 1993). In contrast to colon cancers, endometrial
carcinomas with microsatellite instability tend to be high grade and carry a poorer
prognosis (Caduff et al., 1996). Microsatellite instability can also be seen in 67% of
pancreatic carcinomas, 25% of renal carcinomas, 56% of prostatic adenocarcinomas,
45% of small cell lung cancers, 18% of gastric carcinomas and in a small proportion
of ovarian tumours, melanomas, and gliomas (Han et al., 1993; Merlo el al., 1994;
Uchida et al., 1994 & 1995). In contrast, tumours of the breast, testes and lung do
not show a RER phenotype (Peltomaki et al., 1993b). Interestingly, those HNPCC
patients with Lynch type II syndrome have an increased susceptibility to tumour types
which, when sporadic, tend to display microsatellite instability (Lynch et al., 1996).
This could reflect tissue-specific differences in the susceptibility to the genome
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Table 1
Table comparing HNPCC-derived cancers and sporadic colon cancers outlining the
relative contributions of MMR genes to each. PMS1 mutations have only been
identified in a single kindred.
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TABLE 1
HNPCC Sporadic Colon Cancer
Lifetime risk 1 in 200 1 in 20
Frequency of MMR deficiency / RER+ >90% -15%
Prevalence of MMR mutations in RER+ tumours 26-70%* -10%
Breakdown of MMR mutations in colorectal




[* Data from Liu et al., 1996a & Wijnen et al., 1998]
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destabilising effects of defective mismatch repair. Mutations in hMSH2 and hMLHl
have been identified many RER+ sporadic tumours although it is likely that other
mismatch repair enzymes play an important role (Chung & Rustgi, 1995; Kobayashi et
al, 1996).
p53 and colorectal cancer
p53 is the most commonly mutated gene in human malignancy and is mutated in 50%
of all colorectal carcinomas (Hollstein et al., 1991; Khine et al., 1994). p53 acts as a
tumour suppressor gene with many cancers showing loss of one p53 allele (loss of
heterozygosity) and inactivation of the second allele by point mutation (Chang et al.,
1993). However, certain mutants may also bind to and inactivate the remaining wild-
type allele by a dominant negative inhibition (Vogelstein & Kinzler, 1992).
Furthermore, there is evidence that a cell with only one copy of functional wild-type
p53 is predisposed to malignancy (L. Donehower, personal communication). Loss of
heterozygosity of chromosome 17p, where the p53 gene is located, is infrequent in
adenomas of any stage suggesting that loss of p53 function is associated with the
transition of a benign adenoma to a malignant carcinoma.
p53 structure and function
One of the many functions ascribed to p53 is that it acts a transcription factor that
enhances the rate of transcription of several genes which carry out the /?53-dependent
functions of a cell, including cell cycle arrest, DNA repair and apoptosis (Levine,
1997). p53 exists as a tetramer (Jeffery et al., 1995) and contains a sequence-specific
DNA binding domain and also a transcriptional activation domain that interacts with
the basal transcriptional machinery to both positively and negatively regulate gene
expression (Haffner & Oren, 1995). More than 90% of the missense mutations
identified localise to the sequence-specific DNA binding domain, thus abolishing its
control over gene expression (Hollstein et al., 1994).
In normal cells p53 protein is maintained at low levels by its short half life of
approximately 20 minutes (Maltzman & Czyzyk, 1984). Under conditions of cellular
stress including DNA damage (e.g. y-irrradiation, UV-irradiation, or chemical
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damage), hypoxia or depletion of ribonucleotide triphosphate pools, p53 is
upregulated, stabilised and activated with engagement of transcription (Lane, 1992;
Graeber et al., 1996; Linke et al., 1996). Genes known to be transactivated include
p21, MDM-2, GADD45, Bax, and insulin-like growth factor-binding protein 3 (IGF-
BP3) (Levine, 1997). Activation of p21, which inhibits cyclin-dependent kinases,
results in cell cycle arrest at both Gi/S and G2/M phases, preventing cells from both
entering the cell cycle or completing mitosis (Cox & Lane, 1995). In addition, p21
interacts with proliferating cell nuclear antigen (PCNA) blocking the role of PCNA as
an auxiliary DNA polymerase factor in DNA replication, but not its role in DNA
repair (Cox & Lane, 1995). Those cells bearing excessive DNA damage or incomplete
repair are thought to be deleted by apoptosis. Apoptosis can be initiated directly
through p53 in the absence of transcription or alternatively through the transcription
of Bax (Miyashita & Reed, 1995). Bax dimers are thought to initiate apoptois by
binding to and removing functional Bcl-2, a strong inhibitor of apoptosis (White,
1996). Thus, p53 co-ordinates the cell cycle, and DNA repair mechanisms and can
also initiate apoptosis to prevent the propagation of mutant daughter cells (Lane,
1992). Hence, in the absence of p53, it is predicted that DNA damage and ensuing
mutations are passed on to daughter cells increasing the likelihood of conversion to
malignancy.
p53 and genomic instability
By acting as a cellular gatekeeper for growth and division and thus controlling the
cellular response to DNA damage, p53 is responsible for maintaining the integrity of
cellular DNA and has been dubbed "the guardian of the genome" (Lane, 1992).
Hence, loss ofp53 results in increased genomic instability and is positively correlated
with the development of aneuploidy within colorectal tumours (Livingstone et al.,
1992; Carder et al., 1993; Wyllie et al., 1994). Four pieces of evidence support p53
as a key player in maintaining a stable genome. First, the C-terminal domain ofp53
itself is capable of recognising insertion/deletion DNA mismatches (Lee et al., 1995).
Second, absence of p53 is correlated with gene amplification, thought to arise from
non-homologous recombination in a bridge-breakage-fusion cycle (Yin et al., 1992).
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Third, when mitotic spindle inhibitors are added to wild-type p53 cells, the cells are
arrested in G2. However, in the absence ofp53, these cells reinitiate DNA synthesis
increasing the ploidy of cells (Cross et al., 1995). Finally, p53 is essential to the
regulation of centromere number and subsequent aneuploidy (Fukasawa et al., 1996).
Two pathways to colorectal tumourigenesis
When comparing RER' colon cancers with microsatellite instability (both sporadic
and HNPCC derived) to RER" colon tumours it is clear that they behave differently
both in terms of their clinical features and their molecular pathogenesis. This suggests
that at least two distinct pathways from premalignant cells to carcinoma may exist
(Eshleman & Markowitz, 1996). The more prevalent RER" cancers tend to be
aneuploid in nature and show loss or alteration of large regions of chromosomes
either by mitotic recombination or incomplete segregation at mitosis. At a molecular
level mutations in APC, K-ras, and p53 are common (Kinzler & Vogelstein, 1996).
Inactivation of the p53 gene or the genes involved in chromosome segregation are
thought to play a key role in the initiation this type of instability (Carder et al., 1993
& 1995; Bouffler et al., 1995; Tlsty, 1997).
RER' tumours on the other hand are diploid and do not tend to show random allelic
loss or major chromosomal rearrangements (Schlegel et a!., 1995). Furthermore, they
show a relative paucity of mutations in APC, K-ras and p53 (Shibata, 1996). This
alternative form of genomic instability produces more subtle genetic alterations
throughout the genome perhaps at different growth controlling loci from RER"
cancers (Konishi et al., 1996). For example it is known that RER cancers have a high
incidence of TGF-(3 II receptor mutations of the type usually repaired by the MMR
pathway compared to RER" cancers (Markowitz el al., 1995). Thus, the development
of colon cancers is strongly associated with the acquisition of genomic instability
(Figure C). The mechanisms influencing whether instability arises through gross




At least two different pathways of genomic instability have been identified which
associate with the transition of a premalignant cell to a cancer cell. Defects in p53 or
the controls over chromosomal stability are proposed to lead to gross chromosomal
changes and the development of aneuploidy. In contrast, loss ofDNA mismatch repair
activity results in subtle changes throughout the genome in the form of point











Apoptosis or programmed cell death is a genetically controlled response of cells to a
variety of stimuli to commit suicide. It occurs in a wide variety of physiological and
pathological conditions including tumours. The inhibition of apoptosis in cancers has
been associated with tumour growth, neoplastic progression, and resistance to
cytotoxic anticancer agents (Bellamy et al., 1995; Lyons & Clarke, 1997).
Cell death in tumours
Cell death is a critical determinant of tumour growth (Wyllie, 1985). The two patterns
of cell death in tumours are apoptosis and necrosis and they differ in morphology,
incidence, and regulation. Apoptosis usually affects single cells surrounded by viable
neighbours. Apoptosis is a genetically programmed mode of cell death that is
regulated by many genes, including oncogenes and oncosuppressor genes, which may
be mutated, deleted or abnormally expressed in neoplasms, thus altering tumour cell
susceptibility to apoptosis (Arends, 1995). In contrast, necrosis often occurs in
confluent zones and results from severe non-physiological perturbation of the cellular
environment, such as hypoxia due to inadequate blood flow in tumours (Wyllie,
1981). The topography of necrosis in tumours is a complex function, the major
determinant of which is the rate of proliferation of tumour cells relative to the process
of angiogenesis (Folkmann, 1995). Local regions of rapid tumour expansion may
produce zones of relative hypoxia resulting in necrosis.
The growth rate of a tumour mass is often regarded as a key parameter that is of
fundamental significance for tumour aggression, a major factor in determining the
prognosis for a patient. Proliferation in tumours has been investigated extensively, but
does not correlate well with overall growth. A major reason for this is that net tumour
growth results from the balance of cell gain and cell loss. However, the contribution
of cell loss to tumour growth and aggressiveness is less well understood. In the few
instances where quantitative data are available tumour cell loss is considerable.
Cells may be lost from tumour cell populations by a variety of mechanisms. Cells may
depart the primary tumour site by natural exfoliation or cell migration. They may
leave the proliferating pool of cells by terminal differentiation, or they may die. Many
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descriptions of tumour cell death have often focused on necrosis (Thomlinson &
Gray, 1955; Steel, 1977; Moore, 1983 & 1987), with less extensive study of
apoptosis in tumours (Kerr et al., 1972; Wyllie, 1985). Quantitative estimates of net
tumour cell loss have been made (Steel, 1977; Moore, 1983 & 1987). It is possible to
calculate the potential doubling time (Tp) from estimates of tumour cell production
rates (mitotic indices, nucleotide incorporation or fraction of cycling cells), and the
actual doubling time (Td) from measurements of tumour volume, and so derive the
cell loss factor (CLF = 1 - Tp/Td). The CLF approaches zero with no cell loss, and
unity if extensive loss makes the actual doubling time unmeasurably large. In deriving
CLFs, errors can arise from several inevitable assumptions, but in almost every
tumour studied the CLF is large. In rodent sarcomas and carcinomas CLFs of 0.65 to
0.78, and in human bronchial and colorectal carcinomas and a malignant melanoma
CLFs of 0.73 to 0.96 have been recorded (Steel, 1977; Moore, 1983 & 1987; Kerr &
Lamb, 1984). The high level of tumour CLFs presumably explains the poor
correlation between measures of cell proliferation, such as the thymidine labelling
index, and the tumour volume doubling times for a whole range of human tumours
and points to the considerable importance of tumour cell loss in determining tumour
growth rate (Steel, 1977). Large cell loss factors are likely to act as major regulators
of the rate of tumour expansion and probably determine the overall growth pattern in
terms of tumour enlargement, stasis or regression.
It has been argued that cell death is numerically the most significant form of cell loss
from a growing tumour (Kerr et al., 1972, Wyllie, 1985; Bowen & Bowen, 1990).
This may occur either by necrosis or apoptosis. However, despite the histologically
conspicuous appearance of necrosis, it is by no means established that it can account
for the high levels of cell loss observed in tumours. Apoptosis is less conspicuous
histologically because it has a short timecourse, leaves no residual fingerprints, and
occurs in a scattered distribution within tumours. It is readily calculated that a
surprisingly small proportion of apoptotic cells visualised in a tissue section can
represent very substantial cell loss, and there are increasing quantitative reports on
apoptosis in tumours (Sarraf & Bowen, 1986 & 1988). Indeed the transformation of
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colorectal epithelium to carcinomas has been associated with a progressive inhibition
of apoptosis (Bedi et al., 1995).
Morphology of apoptosis
The morphological changes of apoptosis can be divided into three overlapping phases
(Wyllie et al., 1980 & 1984; Wyllie, 1987; Arends & Wyllie, 1991). In the first, there
is reduction in nuclear size with condensation of chromatin into crescentic caps or
toroids at the periphery of the nucleus. There is a characteristic pattern of
disintegration of the nucleolus, and early in apoptosis cells detach themselves from
their viable neighbours. Associated with the loss of contact regions there is also loss
of specialised surface structures, such as microvilli and the cell initially adopts a
smooth contour. The sudden onset of cell shrinkage, with surface blebbing and
bubbling, sometimes known as zeiosis, is known as phase 1 (Evan et al., 1992). As
the cell shrinks, cytoplasmic organelles become compacted and the smooth
endoplasmic reticulum undergoes dilatation. These dilated cisternae fuse with the cell
membrane, giving rise to a cratered appearance at the surface on scanning electron
microscopy. Cytoskeletal filaments may be seen to aggregate in side-to-side bundles,
parallel to the cell surface, and ribosomal particles are dispersed from the endoplasmic
reticulum and may form semi-crystalline arrays, but otherwise the organelles remain
intact.
In phase 2 apoptosis, there is blebbing at the cell surface and crenation of the nuclear
outline, leading to controlled fragmentation of both nucleus and cytoplasm which split
up into particles of various sizes. Usually, the cell becomes a cluster of round,
smooth, membrane-bounded "apoptotic bodies", some containing variably-sized,
spherical, nuclear fragments of condensed chromatin. These bodies are phagocytosed
by neighbouring viable tumour cells or macrophages (Wyllie et al., 1980).
In phase 3 apoptosis, the residual nuclear and cytoplasmic structures undergo
progressive degradation. Apoptotic nuclear masses lose their smooth, rounded
appearance but are still recognisable as apoptotic as they consist of condensed
chromatin forming unusual shapes with irregular outlines. In tissues these changes
usually occur within the phagosome of the ingesting cell Eventually membranes
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disappear, organelles become unrecognisable and the appearance is that of a residual
lysosomal body. This is the appearance of the majority of apoptotic bodies seen by
light microscopy and sometimes the smooth outline of the surrounding phagosome,
but earlier phases can also be recognised by their rounded contours and deeply
hyperchromatic, fragmented nuclei. Apoptotic cells remain recognisable within tissues
for 2 to 9 hours, a timecourse which coincides with that of complete degradation of
other large biological structures within the phagosomes of macrophages. This
relatively short period ensures that high rates of apoptosis produce only small
increases in the proportion of apoptotic cells observed in tissue sections.
Control of apoptosis in tumours
Apoptosis is a genetically controlled process that can be regulated internally by
various oncogenes and tumour suppressor genes, and also by external signals
including cytokines, cellular ligands (e.g. fas), matrix attachment, chemotherapeutic
drugs, and irradiation (Bellamy et a/., 1995). Expression of c-Myc, wild-type p53, and
APC enhance susceptibility to apoptosis, whereas Bcl-2, retinoblastoma gene product
(.Rb) and Ha-ras, protect against or suppress apoptosis (Hockenbery et al., 1990;
Evan et al., 1992; Clarke et al., 1992 & 1993; Arends et al., 1993 & 1994; Morin et
al., 1996). Cellular sensitivity or resistance to apoptosis in response to one type of
stimulus is often associated with similar sensitivity or resistance to a variety of other
agents (Wyllie, 1987; Bertrand et al., 1991). It is postulated that this is because some
cell types are "primed" for apoptosis and that different oncogenes and tumour
suppressor genes stimulate or suppress the "priming events" for apoptosis by
modulating the expression of a number of effector proteins in apoptosis, for example
ICE-like proteases, endonucleases or transglutaminases (Wyllie, 1980; Arends et al.,
1990; Arends & Wyllie, 1991) Thus, whether a cell undergoes apoptosis in response
to an external stimulus, such as injury due to mild or moderate ischaemia/hypoxia, or
treatment with cytotoxic drugs or irradiation, depends on to what extent it is primed
and hence susceptible to the triggering of apoptosis. For example, in transplanted
tumours expressing wild-type p53, regions of hypoxia mapped to zones that were
enriched for apoptosis, whereas in />5i-deficient tumours hypoxic regions contained
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little apoptosis (Graeber et al., 1996). Hypoxia can induce p53 expression apparently
by a different pathway than DNA-damaging agents (Graeber et al., 1994). Hypoxia
induces apoptosis in malignant cells and this appears to be largely p53 mediated, such
that loss of the p53 gene or overexpression of Bcl-2, substantially reduces hypoxia-
induced cell death (Graeber et al., 1996). Hypoxia is a stress that is commonly found
in growing solid tumours of diverse origin above l-2mm in size. The ability of cells to
survive hypoxia therefore represents a powerful and widely prevalent selection
pressure, suggesting an explanation for why p53 is one of the most commonly
mutated genes in human cancer.
MURINE MODELS OF COLORECTAL CANCER
Individuals inheriting the same mutation predisposing to cancer may show very
different outcomes, ranging from early onset of aggressive cancer to disease free
survival. Experimental mouse models can provide a powerful tool to identify factors
in the environment and genetic background that account for such modifications.
Furthermore, mouse models can provide in vivo experimental systems and also the
opportunity to test chemotherapeutic drugs prior to clinical use. The murine models
of human neoplasia used in this study are outlined below.
Min mouse
The Min (Multiple intestinal neoplasia) mouse was generated by random germline
mutagenesis with N-ethyl-nitrosourea and is heterozygous for a nonsense mutation at
codon 850 of APC (Moser et al., 1990; Su et al, 1992). This strain closely models
the human FAP cancer syndrome, with mice developing numerous adenomas in the
small intestine and colon, some of which progress to become locally invasive
adenocarcinomas. The exact number of adenomas which develop is strongly
influenced by the genetic background of the strain and a second locus termed
Modifier ofMin-1 (Mom-1) (Dietrich et al., 1993). On a sensitive {Mom-1 negative)
C57BL/6J genetic background, in excess of 50 tumours develop per animal leading to
an average life span of 120 days (Dove et al., 1994). The gene encoding this strain
difference has recently been identified as the Pla2g2a gene, which codes for secretory
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phospholipase A2 (MacPhee et al., 1995). This enzyme is involved in synthesising
prostaglandins, hormone-like fatty acids that are believed to regulate colon cell
proliferation (Prescott & White, 1996). Thus, mice resistant to colon cancer (Mom-1
positive) carry functional Pla2g2a, while susceptible (Mom-1 negative) mice carry a
stop mutation in the Pla2g2a gene (Cormier et al., 1997).
The Min mouse varies from human FAP in two important ways. First, the adenomas
in the Min mouse are most prominent in the small intestine while in the human it is the
colon that is the site of most lesions. The differential expression of the oncogene Bcl-
2 between the small intestine and the colon of mice, and its control over apoptosis,
may account for this difference (Merritt et al., 1995). Second, the mechanism of loss
of the remaining wild-type allele is different between mice and humans. In the mouse,
in 100% of adenomas examined, the entire chromosome 18 is lost (Luongo et al.,
1994). In humans loss of the remaining allele can only be detected in 71% of
adenomas and occurs by intragenic inactivating mutations or interstitial deletions
(Ichii et al., 1992; Nagase & Nakamura, 1993). The reason for this difference is
unknown, but one interpretation is that the mouse genome permits hemizygosity,
because inbred strains have been bred to lack recessive lethal mutations.
p52 gene targeted mice have been crossed to Min mice generating progeny that are
APC +lMm p53 -/- (Clarke et al., 1995). Interestingly, given that 50% of colorectal
carcinomas have a mutation in p53 and the role of p53 in maintaining genomic
stability, no increase in the number or acceleration in the development of adenomas
was observed in the intestines. However, there was a shift in phenotype with 83% of
animals possessing abnormalities in the exocrine pancreas, with 22% displaying overt
malignacy (Clarke et al., 1995). Hence, p53 and APC can co-operate in
tumourigenesis although this synergism appears to be tissue specific.
/^-deficient mice
Several strains of mice have been developed which bear constitutive inactivations of
the p53 gene (Donehower et al., 1992; Clarke et al., 1993; Lowe et al., 1993a; Jacks
et a/., 1994). Mice homozygous for these mutations are viable, but a significant
proportion (23%) of female p53 -/- mice die during embryogenesis from neural tube
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defects including exencephaly and subsequent anencephaly (Sah et al., 1995;
Armstrong et al., 1995). Surviving animals rapidly develop spontaneous tumours,
predominantly thymic lymphomas with a smaller proportion succumbing to sarcomas,
by the age of six months (Donehower et al., 1992; Jacks et al., 1994; Purdie et al.,
1994). p53 +/- heterozygote mice develop both lymphomas and sarcomas in similar
ratios although they exhibit a longer latency period before development of the
tumours when compared to homozygote mice (Purdie et al., 1994). In addition, the
heterozygote mice develop a broader spectrum of tumours albeit at low levels
including adenocarcinomas of the lung, pituitary and rarely colon. Indeed, the tumour
spectrum of the p53 +/- mice resembles to some extent that of Li-Fraumeni families
suggesting that the p53 +/- mouse is a useful model for the Li-Fraumeni syndrome (Li
& Fraumeni, 1969; Purdie et al., 1994). Recently, it has been reported that in the
tumours arising in p53 +/- mice approximately 50% retain an intact, functional, wild-
type p53 allele. Tumours which retain the remaining wild-type p53 allele tend to arise
later and display less chromosomal instability (L. Donehower, personal
communication). Thus, a reduction in p53 dosage alone may be sufficient for tumour
development.
To examine the synergism between MSH2 and p53, both of which are known to affect
genomic stability and mutation rates, Cranston et al. (1997) interbred MSH2 and p53
null mice together to generate MSH2 -I- p53 -/- mice. Combined MSH2 and p53
ablation resulted in developmental arrest of all female embryos at 9.5 days (Cranston
et al., 1997). The exact cause of the female embryonic lethality remains unexplained,
although embryos underwent "global catastrophic apoptosis". Viable male mice
however succumbed rapidly to lymphomas, more rapidly than either MSH2 -/- or p53
-/- alone, demonstrating co-operativity between the two genes. Furthermore, in
tumours from MSH2 -/- p53 -/- mice the frequency of microsatellite instability was
not significantly different from MSH2 -/- mice alone, demonstrating that p53 status
does not affect microsatellite instability. Flence, MSH2 and p53 can co-operate to
accelerate tumourigenesis independently of each other by two separate mechanisms.
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MS7/2-deficient mice
Mice with a homozygous deletion in the murine MSH2 gene have been generated (de
Wind et al., 1995; Reitmair et al., 1995). They have defective DNA mismatch repair
and succumb to cancer. Homozygous MSH2 -/- mice develop lymphomas beyond 2-3
months of age, which show microsatellite instability (de Wind et al., 1995; Reitmair et
al., 1995 & 1996a). However, in 70% of mice surviving past 6 months of age,
adenomas and carcinomas with microsatellite instability can be identified in the
intestines providing a good model for the study of HNPCC (Reitmair et al., 1996a).
Furthermore up to 7% of these animals developed skin neoplasms analogous to those
of the Muir-Torre syndrome (Reitmair et al., 1996a). MSH6 (GTBP) deficient mice
have recently been generated and are similar to MSH2 -/- mice developing both
lymphomas and gastrointestinal tumours although they differ from MSH2 -/- mice
displaying an extended life span, an increase in B-cell derived lymphomas and an
absence of microsatellite instability in the tumours that develop (Edelmann et al.,
1997).
By crossing Min mice to MSH2 -/- mice progeny were generated that were
heterozygous for Min and null for MSH2 and therefore possessed absent DNA
mismatch repair. In such progeny adenomas were both greater in number and
developed more rapidly than in the Min controls, leading to reduced survival of the
mice (Reitmair et al., 1996b). Analysis of adenomas from these APC +/Mm MSH2 -/-
mice showed that only a small fraction demonstrated loss of heterozygosity at the
wild-type APC allele (Reitmair et al., 1996b). It is presumed that MSH2 deficiency
confers a mutator phenotype upon the cell resulting in point mutation of the remaining
allele and is thus responsible for the increased formation of tumours. Indeed, in RER
human colorectal tumours a substantial excess of mismatch type APC mutations can
be identified (Huang et al., 1996). Interestingly, defective mismatch repair and
accelerated tumourigenesis has been documented in the clinical setting with rapid
transition from adenoma to carcinoma being observed in HNPCC patients undergoing
routine colonoscopies (Vasen et al., 1995).
Although great strides into the evolution of colorectal cancer and its genetic control
have been made through the study of tumours and mouse models of colorectal cancer,
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a relative lack of knowledge exists in our understanding of the initial stages of
carcinogenesis within normal intestinal crypt cells. For example, knowledge of the
factors regulating apoptosis within crypt cells remain elementary, as does the
contribution of apoptosis to the development of initiated stem cells. In addition, the
available data on the contribution of MSH2 to the in vivo mutation rate of intestinal
cells is subject to a number of confounding factors. Furthermore, no data exists on the
co-operation of the two established forms of genomic instability within cells which
drive tumourigenesis. It is the these very early steps in colorectal tumourigenesis, and





The aim of this study was to investigate the role of the murine MSH2 gene in
tumourigenesis. Specific areas of focus included apoptosis, in vivo mutation
frequency, and interaction with other tumour suppressor genes including p53 and
APC.
Specific questions included:
1. Is MSH2 involved in regulating apoptosis in vivo following genotoxic damage?
2. If correct, is this form of apoptosis dependent upon p53?
3. What is the role of fZ-Alkylguanine-DNA-alkyltransferase (AGT) in modulating
MS7/2-dependent apoptosis?
4. How does the MSH2 status affect in vivo mutation rate?
5. Are the consequences ofMSH2 deficiency altered in environments mutant for p53
and APC, and indeed is there any direct interaction between these genes?







MSH2 has been primarily characterised by its ability to recognise mismatches as a
heterodimer with the GTBP (MSH6) protein (Drummond et al., 1995; Kolodner,
1995) and as a direct consequence of failure of this process, microsatellite instability
and mutation rates are increased in MSH2 -/- cells (de Wind et al., 1995; Reitmair et
al., 1997). However, the consequences ofMSH2 deficiency are complex, with MSH2
-/- cells also showing hyper-recombination, failure to undergo G2 arrest following
DNA damage, and increased survival following exposure to methylating agents in
vitro (de Wind et al., 1995; Hawn et al., 1995). Methylating agents are a diverse
group of compounds which share the potential to transfer alkyl groups (-CH3) to
biologically important macromolecules, especially DNA. Alkylation of cellular DNA
by the compound N-methyl-N'-nitro-N-nitrososguanidine (MNNG) or two
therapeutic alkylating compounds Dacarbazine and Temozolomide occurs at a number
of sites within DNA, the most prevalent of which is the O6 position of guanine
(Swann, 1990). It is thought that O^-methylguanine is responsible for both the
antineoplastic and carcinogenic properties of these compounds (Karran & Bignami,
1992). DNA replication of fZ-methylguanine base pairs results in the formation of O6-
methylguanine:thymine mispairs. Futile attempts to correct this mismatch base pairing
by the DNA mismatch repair pathway results in the repeated generation of single
strand DNA breaks (Branch et al., 1993; Karran & Bignami, 1994). It is these DNA
strand breaks that are postulated to mediate cell death, perhaps through p53 (Nelson
& Kastan, 1994; Rafferty et al., 1996). Cell lines or tumours defective in components
of the mismatch repair pathway would be predicted to be resistant to the cytotoxic
effects of alkylating agents. Results from several different tumour cell lines deficient in
mismatch repair are consistent with this hypothesis (Koi et al., 1994; Branch et al.,
1995; Liu et al., 1996b; Aebi et al., 1997).
The antitumour agent cA-diamminedichloroplatinum (Cisplatin) is used in the
treatment of several types of tumour and introduces cytotoxic DNA damage
predominantly in the form of 1,2 diguanyl intrastrand crosslinks (Eastman, 1983).
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MSH2 is thought to be important in mediating the cellular cytotoxicity of Cisplatin for
three reasons. First, the Cisplatin 1,2 intrastrand adducts can be directly recognised by
the MSH2/GTBP complex (Duckett et al., 1996; Yamada et al., 1997). Second, cell
lines deficient in either MSH2 or MLH1 are tolerant to the cytotoxic effects of
Cisplatin in vitro (Anthoney et al., 1996; Drummond et al., 1996; Aebi et al., 1996).
Finally, in vivo MSH2 -/- xenografts in nude mice are significantly less responsive to
Cisplatin than MSH2 +/+ tumours (Fink et al., 1997).
Flence, there is considerable evidence to suggest that MSH2 status of a cell may affect
its survival following the introduction ofDNA damage normally recognised by MSH2.
Therefore, the hypothesis was formulated that MSH2 is involved in the regulation of
apoptosis. At present no direct evidence exists for a role of MSH2 in regulating
apoptosis in vitro or in vivo, since previous studies have focused only on cell survival
or clonogenicity. To test this hypothesis that MSH2 regulates apoptosis, wild-type
mice and mice bearing a targeted null mutation of MSH2 were exposed to MNNG,
Temozolomide, Dacarbazine and Cisplatin. The nature and prevalence of apoptosis
within their small intestines was studied.
Results
Can methylating agents and Cisplatin induce apoptosis in the small intestine of
MSH2 +/+ andMSH2 -/- mice?
Cohorts of mice, either MSH2 +/+ or MSH2 -/-, were injected with the DNA
damaging agents MNNG, Temozolomide, Dacarbazine, and Cisplatin. Mice were
killed and their intestines removed and fixed at various time points post-injection.
Haematoxylin and eosin (H&E) sections were prepared and the prevalence of
apoptotic bodies in 50 half crypts was counted using the Highly Optimized
Microscope Environment (HOME; see Materials and Methods). In both MSH2 +/+
and MSH2 -/- mice all four compounds induced small intestinal crypt cell apoptosis at
levels significantly higher than baseline rates (Figure 1.1). The number of apoptotic
bodies observed in individual crypts varied and ranged from zero up to a maximum of
approximately twenty-five. Apoptotic bodies were particularly prevalent in the lower
half of the crypt with a marked lack of, or near-total absence of, apoptotic cells in the
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Figure 1.1
(A) H&E stained section of untreated wild-type (MSH2 +/+) murine small intestine.
No apoptotic bodies are visible. (X250)
(B) H&E stained section of small intestine from a MSH2 +/+ mouse injected i.p. with
lOOmg/kg Temozolomide 6 hours previously. Arrows mark apoptotic bodies visible
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upper half of the crypt. The morphology of the apoptotic bodies induced by the
different compounds was identical. In addition, the morphology of apoptosis observed
in MSH2 -/- mice was indistinguishable from that observed in MSH2 +/+ mice.
Which population of cells undergo apoptosis following exposure to methylating
agents and Cisplatin?
In order to characterise which population of cells within the crypt underwent
apoptosis, cumulative counts of one hundred apoptotic bodies were performed in
MSH2 +/+ and MSH2 -/- mice treated with MNNG, Temozolomide, Dacarbazine, and
Cisplatin. Each apoptosis was assigned a crypt position from 1 to 22 as previously
described by Potten (1990). The peak incidence of apoptotic bodies at six hours post-
injection occurred at positions four, five, and six within the crypt with all four
reagents (Figure 1.2 A-D). Positions four, five, and six are thought to represent the
stem cell region of the small intestinal crypt (Potten, 1990). MSH2 +/+ cells and
MSH2 -/- cells showed closely similar patterns in the distribution of apoptotic bodies
within the crypts irrespective of the drug used. No apoptotic bodies were recorded
above position 18 in the crypt for any drug at six hours.
Does MSH2 status alter the level or the kinetics of apoptosis recorded in the small
intestine following treatment with methylating agents and Cisplatin?
Cohorts ofMSH2 +/+ and MSH2 -/- mice were injected with MNNG, Temozolomide,
Dacarbazine and Cisplatin at time zero. The prevalence of apoptotic bodies at 0, 3, 6,
12, 24, 48, and 72 hours post-injection was recorded (Figure 1.3 A-D). Peak
prevalence of apoptotic bodies in both MSH2 +/+ and MSH2 -/- mice was observed at
between 6 and 12 hours post-drug administration (except Dacarbazine which had a
peak at 12 to 24 hours), with a mean of between five and eight apoptotic bodies per
crypt recorded at this time point. The kinetics of apoptotic induction were similar for
MNNG, Temozolomide, and Cisplatin with the apoptotic levels returning to near
basal rates by 48 to 72 hours (Figure 1.3 A, B, D). Dacarbazine displayed different
kinetics from the other compounds with a prolonged peak of apoptosis from 12 to 24
hours (Figure 1.3 C). No difference in the basal levels of apoptosis was observed
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Figure 1.2 (A&B)
Cumulative counts of one hundred apoptotic bodies were performed in MSH2 +/+ and
MSH2 -/- animals. Each apoptosis was assigned a crypt position from 1 to 22.
Apoptosis was scored 6 hours after exposure to (A) 50mg/kg MNNG and (B)







Cumulative counts of one hundred apoptotic bodies were performed in MSH2 +/+ and
MSH2 -/- animals. Each apoptosis was assigned a crypt position from 1 to 22.
Apoptosis was scored 6 hours after exposure to (C) 150mg/kg Dacarbazine and (D)













Cohorts ofMSH2 +/+ or MSH2 -/- animals were given i.p. injections of (A) 50mg/kg
MNNG and (B) lOOmg/kg Temozolomide at time zero. The data show the means of
the prevalence of apoptotic bodies per 50 half crypts at various time points after drug
administration. Each point represents data from a minimum of 3 mice. Closed circle
symbols, MSH2 +/+; open circle symbols, MSH2 -/-. Error bars represent standard
error of the mean (sem).
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Figure 1.3 (C&D)
Cohorts of MSH2 +/+ or MSH2 -/- animals were given i.p. injections of (C)
150mg/kg Dacarbazine and (D) lOmg/kg Cisplatin at time zero. The data show the
means of the prevalence of apoptotic bodies per 50 half crypts at various time points
after drug administration. Each point represents data from a minimum of 3 mice.
Closed circle symbols, MSH2 +/+; open circle symbols, MSH2 -/-. Error bars
represent sem.
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between untreated MSH2 +/+ and MSH2 -/- mice. However, following reagent
administration MSH2 -/- mice displayed markedly lower levels of apoptosis compared
to wild-type (MSH2 +/+) controls, with an MSH2-dependent decrease in apoptosis
observed only after 12 hours in the case of Dacarbazine. In addition, the ratio of the
levels of apoptosis observed in the presence and absence of MSH2 varied with drug
type, with the greatest reduction in apoptosis in the absence ofMSH2 being observed
with Temozolomide and the least for Cisplatin. At peak prevalence of apoptosis
MSTO-deficiency conferred a 9.9, 3.0, and 1.5-fold reduction in apoptosis following
Temozolomide, MNNG, and Cisplatin respectively (p<0.05 for all drugs, Mann-
Whitney U). Notwithstanding the lower levels of apoptosis, the kinetics of induction
of apoptosis in MSH2 -/- cells were closely similar to those in MSH2 +/+ cells.
Does a dose-response relationship exist between the dose of Temozolomide
administered and the level of intestinal apoptosis recorded? Does MSH2 status affect
this relationship?
Cohorts of mice either MSH2 +/+, MSH2 +/-, or MSH2 -/- were injected with a range
of doses of Temozolomide from 25mg/kg to 500mg/kg. The prevalence of apoptotic
bodies in the small intestine was recorded. Temozolomide induced apoptosis in wild-
type, heterozygote, and homozygote MSH2 mice above basal levels at all doses. This
was performed initially as one large experiment and suggested that a dose response
relationship may exist. However, pooled data from other relevant Temozolomide
experiments demonstrated that no dose response relationship existed in wild-type and
heterozygote mice between increasing doses of Temozolomide and the prevalence of
apoptotic bodies recorded (Figure 1.4). The inclusion of such additional data
highlights the inter-experimental error inherent to the calculation of the prevalence of
apoptosis. The possible reasons for such error is addressed in the Materials and
Methods section. However, an approximately linear relationship still existed in
homozygote MSH2-/- mice. Homozygote mice MSH2-/- also displayed significantly




Cohorts of MSH2 +/+, MSH2 +/-, MSH2 -/- mice injected i.p. at time zero with a
range of doses of Temozolomide (25mg/kg to 500mg/kg). Mice were sacrificed six
hours post-injection and intestinal apoptosis scored. Closed circle symbols, MSH2
+/+; closed triangle symbols MSH2 +/-; open circle symbols, MSH2 Each point
represents data from a single mouse.
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Is a single copy ofMSH2 able to couple DNA damage of mismatch type to apoptosis
efficiently?
The prevalence of apoptosis in MSH2 +/+, MSH2 +/- (which only have one functional
copy of MSH2) and MSH2 -/- mice was scored at 0, 3, 6, 12, 24, 48, and 72 hours
after injection with lOOmg/kg Temozolomide (Figure 1.5). Temozolomide induced
high levels of apoptosis in both MSH2 +/+ and MSH2 +/- mice with peak levels
occurring between 6 and 24 hours. By 72 hours the levels of apoptosis had returned
to near basal rates. The kinetics of apoptosis induction were similar in MSH2 +/+ and
MSH2 +/- mice, with no delay or reduction in absolute level being observed in
heterozygotes compared to wild-types (p>0.2, Mann-Whitney U). MSH2 -/-
homozygote mice displayed similar kinetics to wild-type and heterozygote mice
although the levels of apoptosis were markedly reduced at all time points between 6
and 48 hours post-injection when compared to wild-type or heterozygote mice (p<
0.001, Mann-Whitney U).
Does the reduction in the level of apoptosis observed in MSH2 -/- mice following
methylating agents result from MSH2 acting as a non-specific sensor of DNA
damage or as a sensor ofspecific categories ofDNA damage such as methylation?
Cohorts ofMSH2 +/+ and MSH2 -/- mice were exposed to 4 Gray of y-irradiation, a
dose shown to be effective in inducing apoptosis in small intestinal epithelium in
previous experiments (Clarke et al., 1994). y-irradiation induces DNA strand breaks
which are not known to be recognised by MSH2. The prevalence of apoptotic bodies
in the small intestine was determined at 0, 4, 8, 24, 36, 48 and 60 hours post-
irradiation (Figure 1.6). MSH2 +/+ or MSH2 -/- mice behaved identically in their
apoptotic response with a rapid induction of apoptosis observed at four hours. This
was followed by a decrease in the levels at eight hours with a second smaller peak of
apoptosis being observed at 24 hours. Apoptotic frequencies returned to basal levels
by 60 hours. No significant (p>0.4, Mann-Whitney U) difference in the prevalence of




Cohorts of MSH2 +/+, MSH2 +/-, MSH2 -/- mice injected i.p. at time zero with
lOOmg/kg Temozolomide. A minimum of three mice were sacrificed at each time
point and intestinal apoptosis scored. Closed circle symbols, MSH2 +/+; closed
triangle symbols MSH2 +/-; open circle symbols, MSH2 Error bars represent sem.
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Figure 1.6
Cohorts of MSH2 +/+ and MSH2 -/- mice were exposed to 4 Gray of ionising y-
irradiation at time zero. Mice were killed at the indicated time points and intestinal
apoptosis scored. Each point represents data from a minimum of three mice. Closed
circle symbols, MSH2 +/+; open circle symbols, MSH2 Error bars represent sem.
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Discussion
To test directly if MSH2 has a significant role in the induction of apoptosis in vivo
MSH2 +/+ and MSH2 -/- mice were exposed to the methylating agents MNNG,
Temozolomide, and Dacarbazine, and also to the cross-linking agent Cisplatin. All
these compounds are known to induce DNA damage which is specifically recognised
by MSH2 (Karran & Bignami, 1992; Liu et al., 1996b; Yamada et al., 1997). The
prevalence of apoptotic bodies within the small intestine was scored by microscopy.
The murine small intestine was used as an in vivo model for the study of apoptosis for
three principal reasons. First, the known intestinal expression of MSH2 (J. Bubb,
personal communication; Leach et al., 1996). Second, the demonstrated role of
MSH2 in the prevention of intestinal neoplasia. Third, because apoptosis within the
murine small intestine has been well characterised previously (Potten, 1990; Clarke et
al., 1994 & 1997). If MSH2 is involved in the induction of apoptosis after DNA
damage induced by these agents, then lack of MSH2 is hypothesised to abolish any
coupling between such DNA damage and apoptosis.
In both MSH2 +/+ and MSH2 -I- mice, all methylating agents and Cisplatin induced
levels of apoptosis significantly higher than background rates alone. This novel finding
was anticipated in view of previous work by Potten et al. (1992 & 1997)
demonstrating that following a variety of DNA damaging agents, crypt cell apoptosis
ensues. Apoptosis occurred at peak levels within the stem cell compartment of the
crypt in both MSH2 +/+ and MSH2 -/- mice following exposure to methylating agents
with the mode lying between positions 4 and 6 (Potten, 1990). This pattern of
apoptosis was similar to that seen in the small intestine following N-nitroso-N-
methylurea (NMU) and y-irradiation, with stem cells in the crypt being the most
susceptible (Potten et al., 1992 & 1997; Clarke et al., 1994). Cisplatin-induced
apoptosis also occured predominantly within the stem cell region of the crypt - again
indicating the specific sensitivity of cells at the stem cell position to apoptosis. MSH2
-/- cells also underwent apoptosis peaking at positions 4 to 6, with MSH2 status
failing to alter the distribution of apoptosis within the crypt. Hence, both MSH2-
dependent and MST/2-independent apoptosis occurred predominantly in the stem cell
compartment.
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The peak prevalence of apoptosis induced by methylating agents occurred in stem
cells, at positions 4 to 6, but not at positions 8 to 10 which is the main site of DNA
replication determined by bromodeoxyuridine (BrdU) incorporation (Potten, 1990;
Clarke et al., 1994). The current hypothesis on the mechanism of action of
methylating agents is that following methylation of guanine bases, f/-methylguanine
must first undergo DNA synthesis with generation of an 06-methylguanine:thymine
mispair, fixing the mutation into the genome. Thus, one possibility is that a high
prevalence of apoptosis in positions 8 to 10 of the crypt might have been expected.
However, this was not found to be the case and the data suggest that methylating
agents induce DNA damage capable of rapidly inducing apoptosis, without the need
for DNA synthesis.
In MSH2 +/+ animals, all of the drugs used induced measurable levels of intestinal
apoptosis and in all cases the peak induction of apoptosis was seen between 8 and 24
hours. In comparison to the pattern observed in the MSH2 +/+ animals, the apoptotic
response of MSH2 -/- mice was significantly diminished for all four drugs. Thus,
MSH2 must play a significant role in murine small intestinal apoptosis induced by
DNA damage of mismatch type. The MSH2 dependency was greatest for
Temozolomide and least for Cisplatin, and only visible after 12 hours with
Dacarbazine. Why should the degree of dependency on MSH2 status vary with drug
type? A simple explanation is that Temozolomide-induced lesions may be specifically
recognised predominantly or almost entirely by MSH2 and the mismatch repair
pathway. By comparison, Cisplatin-induced cross-links which although recognised by
MSH2, may be removed by alternative DNA repair pathways such as the nucleotide
excision repair pathway (Duckett et al., 1996; Moggs et al., 1996). The difference in
the kinetics of apoptosis induced by Temozolomide and Dacarbazine is surprising in
view of the fact that both drugs methylate DNA through the same intermediate 5-(3-
methyl-triazine-1-yl)imidazole-4-carboxamide (MITC) (Stevens et al., 1987; Denny et
al., 1994). However, the method of generation of MITC differs between the two
drugs with Temozolomide reacting spontaneously with water to give MITC, while
Dacarbazine requires oxidative N-demethylation by cytochrome P450 enzymes
(Figure 3.6). This difference in metabolism alone may account for the delay in the
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kinetics of apoptosis in wild-type mice induced by Dacarbazine compared to
Temozolomide. Other non-specific factors that may account for the differences
between drugs include solubility, variations in the metabolic products formed during
breakdown of the compounds, and possible differences in specificity of the alkyl
group transfer may exist (e.g. to proteins and other DNA targets including thymine to
give Cf-methylthymine) (Pegg & Byers, 1992). The reason why Dacarbazine differs in
its MS7/2-dependency from Temozolomide is unknown. However, with all four drugs
tested, absence of MSH2 compromised the ability of cells to enter apoptosis. It
remains possible that the cohort of damaged cells protected from apoptosis by
absence of MSH2 may be removed by death outwith the time span analysed here, or
that these cells may be prevented from propagating by some other mechanism, such as
permanent cell cycle arrest. Nonetheless, the phenomenon of delayed apoptosis which
has been observed in p53 -/- mice following y-irradiation (Clarke et al., 1997; Merritt
et al., 1997) and seen here following Temozolomide (see Part II of this thesis) was
not observed in MSH2 -/- mice. Thus, the most direct conclusion is that a significant
number of cells escape death by virtue ofMSH2 deficiency and are therefore potential
founders of clones bearing unrepaired mutations.
Evidence for a dose response was obtained from one experiment, however, when all
relevant data from other experiments were included this relationship was not
confirmed. This highlights the difficulties with the reproducibility of in vivo apoptotic
data between experiments and the inter-experimental variation that exists. Possible
mechanisms to account for such variations are addressed in the Materials and
Methods as is the methodology used to try to minimise this error. Data from Figure
1.4 does not therefore provide evidence for a relationship between increasing doses of
Temozolomide and the prevalence of apoptosis recorded. Two possible explanations
exist. First, at the doses of Temozolomide used the level of DNA damage induced is
above the critical level required to induce apoptosis in susceptible cells. Thus,
increasing the dose of Temozolmide will increase the level of cellular DNA damage
but not apoptosis. Alternatively, at doses beyond approximately lOOmg/kg
Temozolomide, it is possible that the maximal prevalence of crypt cell apoptosis has
been attained and hence the lack of dose response seen may reflect a limitation in the
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apoptotic assay. It remains possible that such a dose response occurs but this has been
masked by the inter-experimental error. Why should a dose response appear to exist
only for the homozygote MSH2 -/- mice? It is possible that the lower levels of
apoptosis observed allowed a dose response to be recorded as maximal crypt cell
apoptosis had not yet been reached. However, it is also possible that the MSH2 -
independent apoptosis responds proportionately to increasing doses of
Temozolomide. At present no clear explanation exists for the lack of dose response
observed in wild-type and heterozygotes, but not in homozygote mice.
Is a single copy ofMSH2 (as exists in the intestinal cells of HNPCC patients) capable
of linking DNA damage to apoptosis? The apoptotic response of heterozygote MSH2
+/- mice following Temozolomide treatment was closely similar to their wild-type
MSH2 +/+ counter parts. No evidence of a time delay in the onset of apoptosis was
apparent in the heterozygote mice. These results demonstrate that a single functional
allele ofMSH2 is capable of the effective induction of apoptosis even at high levels of
DNA damage, unlike p53 where a single allele compromises the efficiency of coupling
DNA damage to apoptosis (Clarke et al., 1994).
Apoptosis of lower crypt cells can be initiated by exposure to y-irradiation (Clarke et
al., 1994; Merritt et al., 1994 & 1997). y-irradiation is thought to induce DNA strand
breaks which are coupled to apoptosis by /?5i-dependent pathways in the immediate
apoptotic response and to />53-independent pathways in the delayed apoptotic
response. To exclude the possibility that MSH2 was acting as a non-specific DNA
damage sensor or was involved as a effector protein in the apoptotic cascade within
small intestinal cells, MSH2 +/+ and MSH2 -/- mice were irradiated. If either
possibility were true, absence of MSH2 would be expected to compromise the
induction of apoptosis in response to irradiation. However, apoptosis induced by y-
irradiation was quantitatively identical in MSH2 +/+ and MSH2 -/- animals,
demonstrating that MSH2 acts neither as a sensor of generalised DNA damage nor as
an essential general effector protein of apoptosis in intestinal cells. Rather, the
apoptosis-inducing function ofMSH2 appears to be specific for DNA methylation and
to a lesser extent Cisplatin DNA cross-linking, with both types of lesion known to
involve activation of the mismatch repair pathway. Hence, the signal for apoptosis in
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lower crypt cells injured by methylating agents and Cisplatin arises subsequent to and
is specified by recruitment ofMSH2. The precise nature of this signal is unknown but
presumably arises within the complex ofMS7/2-dependent repair proteins and DNA.
The significance of the these findings to carcinogenesis is that cells with absent MSH2
not only have a reduced capacity for DNA repair but also a compromised ability to
enter apoptosis following methylating type DNA damage. Are cells of the intestine
exposed to compounds capable of methylation? The relationship between saturated fat
in the diet and colon cancer is well established (Bresalier & Kim, 1993). Indeed, there
is a positive correlation between high levels of faecal bile acids (which are derived
from fatty acids) and colorectal cancer incidence (Reddy & Wynder, 1973). Bile acid
conjugates of glycoholic and taurocholic acid can undergo N-nitrosation form N-
nitrosamides, very similar compounds to MNNG (Shuker et cil, 1981). Furthermore,
N-nitroso bile acid conjugates are genotoxtic inducing the same spectrum of
mutations that MNNG produces (Puju et al., 1982). Therefore, cells of the small and
large intestine are constantly subjected to nitrosated bile acid conjuates capable of
inducing DNA damage of mismatch type. This has two consequences. First, any cell
with compromised MSH2 function would be predicted to accumulate point mutations
at a greater rate than normal and also by virtue of MSH2 deficiency have a greatly
reduced probability of entering into apoptosis, thus predisposing itself to be a founder
cell of an ensuing malignancy. Second, constant selection pressure from carcinogenic
bile acids may encourage the emergence of methylation tolerant clones of cells. Such
cells would be deficient in mismatch repair, possess the "mutator phenotype" with an
unstable genome conferring a distinct growth advantage on that particular cell.
However, absence ofMSH2 would only be relevant to methylating DNA damage and
not other compounds which can induce alternative forms of DNA damage, since cells
lacking MSH2 exposed to y-irradiation did not compromise their ability to induce
apoptosis. In addition, cells with only one copy ofMSH2 are able to induce apoptosis
effectively. HNPCC patients are therefore likely to possess intestinal cells which are
not compromised in their ability to undergo apoptosis in response to methylating
DNA damage at least initially. However, cells of HNPCC patients which lose the
remaining copy of MSH2 by somatic mutation, may also lose their ability to couple
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DNA damage to apoptosis. Such cells are at high risk of being the founder cell of a
colorectal cancer.
Can the finding that untransformed intestinal cells which lack MSH2 show a reduced
apoptotic potential be extrapolated to tumour cells themselves? This can only be
answered by further in vivo studies of tumour cell apoptosis, tumour growth, and
responsiveness to chemotherapy in MSH2 +/+ and MSH2 -/- cancers. Such studies
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Role ofp53 in MSf/2-dependent Apoptosis
Introduction
Wild-type p53 is a critical regulator of apoptosis in a variety of cell types with loss of
or mutation in p53 compromising the ability of such cells to enter apoptosis (Lowe et
al., 1993b; Lyons & Clarke, 1997). There are a number of reasons why p53 may be
involved in MS7/2-dependent apoptosis in the small intestine following exposure to
methylating agents. First, p53 is known to be a key protein in the apoptotic response
of murine small intestinal crypt cells following DNA damage (Clarke et al., 1994;
Merritt et al., 1997; Potten et al., 1997). For example, following exposure to ionising
irradiation, there is an increase in p53 nuclear immunoreactivity which occurs most
strongly in the stem cell zone. When p53 immunoreactivity and apoptosis are
recorded on a positional basis within the intestinal crypt, they overlay each other
precisely (Merritt et al., 1994). Second, small intestinal crypt cells which lack p53 fail
to undergo apoptosis in response to y-irradiation, with p53 being essential for the
immediate (4 to 6 hour) wave of apoptosis (Clarke et al., 1994; Merritt et al., 1994).
Third, p53 is a critical regulator of the cell cycle and apoptosis in response to a variety
of DNA damaging agents, including methylating agents (Zhan et al., 1993; Lowe et
al., 1993b; Levine, 1997). Lastly, in addition to the role of p53 in controlling cell
cycle and apoptosis there is evidence that p53 itself can act as a sensor of DNA
damage in the form of insertion/deletion mismatches (Lee et al., 1995). This raises the
possibility that p53 may also be involved in direct recognition of the mismatched bases
that arise from the methylation of guanine residues. Thus, for all the above reasons the
MSH2-dependent apoptotic response of small intestinal crypt cells to methylating
agents may require p53.
To address the potential role of p53 in MSH2-dependent apoptosis, p53 null mice
were exposed to methylating agents and Cisplatin. Furthermore, the timecourse of
apoptosis in p53 null mice and mice doubly null for both MSH2 and p53 (MSH2 -/-
p53 -/-) following exposure to Temozolomide was recorded. Hence, the role ofp53
and any interaction with MSH2, in the apoptotic response of murine small intestine to
methylating DNA damage was evaluated.
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Results
Is p53 required for the immediate wave of intestinal apoptosis seen following
exposure to methylating agents and Cisplatin ?
Cohorts ofp53 +/+ and p53 -/- mice (Clarke et al., 1993) were injected with 50mg/kg
MNNG, lOOmg/kg Temozolomide, 150mg/kg Dacarbazine, or lOmg/kg Cisplatin.
Apoptosis was scored in the crypts of the small intestine six hours after drug
administration (Figure 2.1). In p53 +/+ mice high levels of apoptosis were evident
(see Part I of this thesis). However, for all reagents tested, absence ofp53 resulted in
significantly lower levels of apoptosis (p<0.05, Mann-Whitney U) and were similar to
the background levels of spontaneous apoptosis that occur in small intestinal crypts.
Does the phenomenon of delayed p53-independent apoptosis seen following y-
irradiation also occur following Temozolomide administration? If so, does MSH2
status affect it?
Cohorts of p53 -/- mice and mice null for both MSH2 and p53 (MSH2 -I- p53 -/-)
were treated with lOOmg/kg Temozolomide at time zero. Apoptosis was scored at
intervals up to 120 hours post-injection (Figure 2.2). In the small intestines ofp53 null
mice no measurable apoptosis was recorded up to 12 hours. From 24 to 96 hours
levels of apoptosis were elevated and peaked at 72 hours. At no time did the
prevalence of apoptosis reach values associated with wild-type mice. By 120 hours
post-drug administration apoptosis had returned to basal levels. Double mutant
(.MSH2 -/- p53 -/-) mice displayed only baseline levels of apoptosis up to 96 hours
after exposure to Temozolomide. Absence of MSH2 effectively abrogated the p53-
independent apoptotic response of the murine small intestine to Temozolomide.
Does the p53-independent apoptosis induced by Temozolomide treatment alter the
morphology or crypt position of the observed apoptosis?
The morphology of the apoptotic bodies in p53 -/- mice occurring 48 to 72 hours
after injection of lOOmg/kg Temozolomide differed from those seen in wild-type mice,
and occurred mainly in the upper half of the crypt (Figure 2.3). They were
approximately twice the volume and appeared to possess many condensed chromatin
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Figure 2.1
Bar chart showing the mean prevalence of apoptotic bodies in p53 +/+ and p53 -/-
mice six hours after i.p. injections of 50mg/kg MNNG, 100mg/kg Temozolomide,
150mg/kg Dacarbazine, or lOmg/kg Cisplatin. Wild-type data reproduced from Figure
1.3. Each bar represents the data from three mice. Closed bars, p53 +/+; open bars




Timecourse of the levels of apoptosis in p53 +/+ and p53 -/- mice, and also mice
doubly mutant for both MSH2 and p53 following i.p. injection of lOOmg/kg
Temozolomide at time zero. Each point represents data from a minimum of three
mice. MSH2 wild-type data is reproduced from Figure 1.3B. Closed circle symbols,
MSH2 +/+ p53 +/+; open circle symbols, MSH2 +/+ p53 closed triangular
symbols, MSH2 -/- p53 -/-.
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Figure 2.3
H&E stained section of small intestine from a p53 -/- mouse treated with lOOmg/kg
Temozolomide 48 hours previously. Note the size and distribution of the apoptotic
bodies (arrowed) within the crypt compared to those in Figure 1.1. (X250)
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masses. To confirm that this delayed />53-independent apoptosis occurred at higher
crypt positions cumulative counts of one hundred apoptotic bodies were performed in
p53 -/- mice 48 hours after treatment with lOOmg/kg Temozolomide. Each apoptosis
was assigned a crypt position and the frequency of apoptosis at each crypt position
recorded (Figure 2.4). Peak prevalence of apoptotic bodies occurred at positions 13
and 14 which represent the proliferating compartment of the crypt. This differs from
/?53-dependent apoptosis which has a peak prevalence at positions 4 to 6, six hours
post-injection when the prevalence of apoptotic bodies is maximal.
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Figure 2.4
Cumulative counts of one hundred apoptotic bodies in p53 +/+ and p53 -/- mice. Each
apoptosis was assigned a crypt position from 1 to 22. Apoptosis was scored 6 hours
after exposure to lOOmg/kg Temozolomide in p53 +/+ mice and 48 hours in p53 -/-





From the results presented here p53 is required for small intestinal crypt cells to
engage apoptosis following methylating agent or Cisplatin mediated DNA damage 6
hours post-drug administration. A similar critical dependence upon p53 to couple
DNA damage to apoptosis is also observed 4 hours after y-irradiation (Clarke et al.,
1994 ; Merritt et al., 1994). Thus, in lower crypt cells p53 is essential to the
successful generation of an early apoptotic signal following both mismatch-type and
irradiation-type DNA damage resulting in the immediate wave of apoptosis seen in the
first 4 to 6 hours.
The phenomenon of delayed /?5J-independent apoptosis, seen after y-irradiation
(Clarke et al., 1997; Merritt et al., 1997), was observed from 24 to 96 hours
following Temozolomide administration to p53 -/- mice. Furthermore, MSH2 -/- p53
-/- mice failed to show either the early wave or this delayed /z55-independent wave of
apoptosis (p<0.05 at 72 hours; Mann-Whitney U). These data clearly show that, in
response to methylating agent damage, MSH2 is required for the bulk of both the
immediate and delayed apoptotic responses of lower crypt cells. Moreover, although
the signal for apoptosis is processed through p53 where this is available, a death
signal is generated in the absence ofp53 albeit at a reduced level. The reduction in the
number of apoptotic bodies observed in delayed £>5J-independent apoptosis suggests
that /?5J-independent mechanisms are less efficient at coupling DNA damage to
apoptosis. How might p53 interact with MSH22 Although it is not known, one
possible explanation is that p53 links the DNA strand breaks generated by the futile
attempts of the MMR system on the C^-methylguanine:thymine mispairs to an
apoptotic cascade (Nelson & Kastan, 1994; Rafferty et al., 1996).
The morphology of the delayed apoptosis following Temozolmide was very similar to
that observed by Merritt et al. (1994) following y-irradiation. Such apoptosis is
thought to result from aberrant mitosis, and is strongly reminiscent of vincristine
induced apoptosis within the small intestine (Harmon et al., 1992). Thus, it is possible
that in the absence ofp53, a cell bearing DNA damage of mismatch type escapes p53-
induced Gi arrest and proceeds through S-phase unhindered. However, during
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mitosis, damaged DNA is recognised by /Gi-independent pathways and apoptosis
initiated from the G2/M phases of the cell cycle accounting for the alteration in
apoptotic phenotype. The increased nuclear and cellular volume may therefore relate
to the doubled DNA content of the cell following its passage through S phase.
The crypt position with the highest frequency of apoptotic bodies in p53 null mice
was more luminal than in wild-type mice. This may simply result from a combination
of on-going crypt cell migration and a delay in the onset of apoptosis. Over a period
of 42 hours the crypt position with the greatest frequency of apoptotic bodies shifted
nine places towards the lumen (from position 5 to 14). Normally crypt cells migrate at
0.8 cell positions per hour (Kaur & Potten, 1986). However, following irradiation-
induced DNA damage, this figure can fall to 23-30% of the normal rate (Potten,
1990). Given the similarities between Temozolomide and irradiation-induced
apoptosis, it is distinctly possible that Temozolomide may also retard crypt cell
migration. If this assumption can be made then, 42 hours at 0.8 positions per hour
equates to a transit of 34 cell positions, when reduced to 26% would equal 9
positions. Thus, one plausible explanation for the alteration in crypt position is that
stem cells which receive methylating DNA damage at positions 4 to 6 subsequently
migrate slowly up the crypt with time, entering apoptosis in a delayed manner when
they are in the more luminal regions of the crypt.
The implication of these findings to carcinogenesis is that MSH2 and p53 deficiency
may predispose to malignancy not only by failing to repair DNA damage, but also by
failing to engage apoptosis and delete cells (predominantly in the stem cell region of
the crypt) which harbour DNA damage. If this pathway has real significance for the
very early stages of carcinogenesis, it would be predicted that lesions in genes
affecting this pathway, here shown to include both MSH2 and p53, would arise early
in the development of colorectal cancer. This is clearly not the case for the p53 gene,
where loss of function is primarily associated with late events such as the adenoma-
carcinoma transition. The existence of delayed /?5J-independent apoptosis in itself,
suggests that p53 may not be a critical factor in the early stages of malignancy.
Furthermore, the idea that the p53-dependent apoptotic response of intestinal cells
may have limited relevance is supported by experiments analysing the intestinal
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mutation frequency in p53 null mice, where a /?53-dependent increase was only
observed following exposure to very high levels of DNA damage (Clarke et al.,
1997). However, MSH2 may play a more significant role in the initial stages of
carcinogenesis for three reasons. First, loss of DNA mismatch repair may occur early
in colorectal neoplasia (Huang et al., 1996). Second, no evidence of delayed MSH2-
independent apoptosis was observed in MSH2 -/- mice. Thus, in contrast to p53, no
alternative pathway appears to exist in the absence of MSH2 to delete cells with
alkylation damage. Third, absence ofMSH2 significantly increases the mutation rate in
intestinal stem cells, unlike p53 (see Part IV of this thesis). Therefore, the
consequences of failed apoptosis by virtue ofMSH2 deficiency may actually be more
significant than those mediated through p53 deficiency.
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Part III
Role of 06-Alkylguanine-DNA-alkyltransferase in
MA//2-dependent Apoptosis
80
Role of 06-Alkylguanine-DNA-alkyltransferase in
MA//2-dependent Apoptosis
Introduction
The DNA repair protein 06-alkylguanine-DNA-alkyltransferase (AGT) functions by
recognising and removing specific alkyl lesions from DNA (Pegg & Byers, 1992).
Substrates include (/-methylguanine which is believed to be the major pre-mutagenic
lesion induced by methylating agents. AGT mediated repair occurs via the transfer of
the alkyl group to a cysteine residue in the AGT protein, a process which is
stoichiometric and autoinactivating (Pegg, 1990). AGT therefore confers protection
against the mutagenic effects of methylating agents, many of which are of clinical
importance as anti-tumour agents such as Temozolomide (von Hofe & Kennedy,
1992; Dumenco et al., 1993; Liu et al., 1996b). Failure of AGT to repair O6-
methylguanine results in 06-methylguanine: thymine mispairs following DNA
replication and it is postulated that these mediate cell death via mismatch repair
(Karran & Bignami, 1994). In addition, AGT activity is known to be up-regulated in a
/lid-dependent manner in response to DNA strand breaks following ionising
irradiation (Rafferty et al., 1996). Furthermore, AGT protein can be inactivated by
exposure to Cisplatin (Wang & Setlow, 1989), although there are no reports of AGT-
mediated removal of 1,2 diguanyl Cisplatin adducts. Hence, AGT activity may
therefore modulate the levels of observed MSV/2-dependent apoptosis by effectively
removing methylation damage and so suppressing cell death such that the extent of
MS7/2-dependency is underestimated.
To assess the potential role of AGT in MST/2-dependent apoptosis following
methylating agents and Cisplatin, functional AGT activity was depleted by
administering the compound O6-Benzylguanine to mice (Dolan et ah, 1990).
Benzylguanine is a competitive and irreversible inhibitor of AGT which acts by
binding to the -CH3 cysteine acceptor site of AGT forming A-Benzylcysteine (Pegg et
al., 1993). Benzylguanine bound AGT is inactive and is subsequently degraded.
Cellular AGT activity can be restored only by de novo protein synthesis (Pegg &
Byers, 1992) and its depletion by Benzylguanine has been proposed as a useful
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adjuvant to methylating and chloroethylating treatment of tumours in the clinic
(Wedge & Newlands, 1996). Using Benzylguanine to deplete AGT activity in vivo,
would allow the study of MSH2-dependent apoptosis in wild-type and MSH2 null
mice following treatment with methylating agents and Cisplatin. Any bias resulting
from variations in AGT activity would therefore be removed. First, the possibility that
MSH2 status may alter cellular AGT activity levels was investigated.
Results
Does MSH2 status influence the level of resting AGT activity in vivo?
To investigate the possibility that absence of MSH2 led to increased or decreased
AGT levels six to nine male untreated MSH2 +/+ mice and six male untreated MSH2
-/- mice were sacrificed and their tissues removed for the measurement of AGT
activity. Tissues studied included liver, kidney, small intestine, lung, brain, spleen,
testes, colon, bone marrow, and thymus (Figure 3.1). Resting AGT activity was not
significantly different in MSH2 +/+ and MSH2 -/- mice for the majority of tissues
(p>0.06, Mann-Whitney U). However, MSH2 -/- mice displayed significantly lower
AGT activity in both their liver and lungs (p<0.05, Mann-Whitney U).
Can Benzylguanine deplete AGT activity in murine tissues in vivo ?
Wild-type MSH2 +/+ mice were injected with 60mg/kg Benzylguanine at time zero.
Samples of tissue from liver, colon, and small intestine were assayed at several time
points after injection for AGT activity (Figure 3.2). Within one hour of Benzylguanine
delivery AGT activity fell to almost undetectable levels in all three tissues. AGT was
depleted for up to 12 hours in all tissues examined, but after 12 hours functional AGT
activity started to return. Levels of AGT activity similar to those prior to
Benzylguanine delivery returned in all tissues examined by 72 hours. Benzylguanine




AGT activity levels (fmoles/mg) in a range of untreated tissues from MSH2 +/+ and
MSH2 -/- mice. Each bar represents data from six mice. Closed boxes, MSH2 +/+;










Timecourse of the average AGT activity levels (fmoles/mg) in the liver, colon and
small intestine of MSH2 +/+ mice injected i.p. with 60mg/kg Benzylguanine at time
zero. Each point represents data from a minimum of three mice. Closed circle
symbols, liver; open square symbols, colon; open circle symbols, small intestine. Error
bars represent sem.
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Does the administration ofBenzylguanine induce apoptosis within the murine small
intestine?
Addition of Benzylguanine, by inhibiting AGT, may increase endogenous alkylating
DNA damage and thus induce apoptosis. To exclude this possibility cohorts ofMSH2
+/+ and MSH2 -I- mice were injected with 60mg/kg Benzylguanine at time zero.
Apoptosis was scored at 0, 3, 6, 12, 24, 48, and 72 hours after injection (Figure 3.3
A). Neither wild-type nor MSH2 null mice displayed levels of apoptosis above
baseline rates at any point up to 72 hours after Benzylguanine injection.
Does AGT depletion by Benzylguanine alter the prevalence ofapoptosis recorded in
wild-type small intestine following exposure to methylating agents, Cisplatin or y-
irradiation?
To investigate the possibility that endogenous AGT activity was modifying the
observed crypt cell apoptosis, or the extent of DNA damage received by cells at a
given dose, wild-type mice were pre-treated with Benzylguanine (60mg/kg). One hour
later lOOmg/kg Temozolomide, or 50mg/kg MNNG, or 10 mg/kg Cisplatin, or 4 Gray
of y-irradiation were administered. Apoptosis was scored in the small intestine six
hours later (Figure 3.3 B). No significant differences in the prevalence of apoptosis
were observed between Benzylguanine and non-Benzylguanine treated animals (p>0.4
in all cases, Mann-Whitney U).
Is there a difference in the prevalence ofapoptosis following low dose Temozolomide
in the presence and absence ofBenzylguanine?
To exclude the possibility that the doses of methylating agents used in Figure 3.3 B
were inactivating AGT by depleting cellular pools of active AGT, and therefore
rendering Benzylguanine treatment irrelevant, very low doses of Temozolomide
(range 0.5 to 16mg/kg) were administered to mice with and without Benzylguanine
cover. Six hours later apoptosis was scored (Figure 3.3 C). The rationale behind this
approach was that at low doses of Temozolomide not all functional AGT activity
would be abolished by the methylating agent, and thus if AGT could actually alter the
level of apoptosis, a difference between Benzylguanine and non-Benzylguanine
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Figure 3.3
A Graph showing the prevalence of apoptotic bodies in the small intestine of MSH2
+/+ and MSH2 -/- mice at various time points following 60mg/kg Benzylguanine i.p.
Each point represents data from a minimum of three mice. Closed circle symbols,
MSH2 +/+; open circle symbols, MSH2
B Bar chart showing the prevalence of apoptosis in the murine small intestine 6 hours
after reagent administration and 7 hours after i.p Benzylguanine (60mg/kg). Cohorts
ofMSH2 +/+ mice were treated with lOOmg/kg Temozolomide, or 50mg/kg MNNG,
or 1 Omg/kg Cisplatin, or exposed to 4 Gray y-irradiation in the presence and absence
of Benzylguanine. Each bar represents data from six mice. Closed boxes, MSH2 +/+
Benzylguanine-untreated; open boxes, MSH2 +/+ Benzylguanine-treated. Error bars
represent sem.
C Line graph showing the prevalence of apoptosis 6 hours after lOOmg/kg
Temozolomide administration and 7 hours after i.p Benzylguanine (60mg/kg).
Cohorts ofMSH2 +/+ mice were dosed with i.p. Temozolomide (range 0.5-16mg/kg)
in the presence and absence of Benzylguanine pretreatment. Each point represents
data from three mice. Closed circle symbols, MSH2 +/+ Benzylguanine-untreated;

























treated mice may become apparent. No significant differences in the prevalence of
apoptosis were observed between Benzylguanine treated and non-Benzylguanine
treated mice at any of the doses of Temozolomide used (p>0.07 for all doses, Mann-
Whitney U).
In the absence ofAGT is the level of reduction in apoptosis seen in MSH2 -/- mice
following methylating agent or Cisplatin treatment identical to that seen in the
presence ofAGT activity?
To investigate whether AGT could modulate MS7/2-dependent apoptosis cohorts of
MSH2 +/+ and MSH2 -/- mice were injected with 60mg/kg Benzylguanine. One hour
after the administration of Benzylguanine, mice were injected with 100mg/kg
Temozolomide, or 50mg/kg MNNG, or lOmg/kg Cisplatin. Apoptosis was scored in
the small intestine at 6 hours (Figure 3.4). For all reagents tested the level of
reduction in the prevalence of apoptosis recorded in MSH2 -/- mice in the absence of
AGT was not significantly different from the level of reduction observed in the
presence of AGT (p>0.9 for all three drugs, Mann-Whitney U). Thus, AGT does not
modulate MSH2-dependent apoptosis in the murine small intestine following
Temozolomide, MNNG or Cisplatin.
Does AGTplay any role in MSH2-dependent apoptosis in the small intestine? What
is the role ofAGT in Dacarbazine-induced apoptosis?
In order to assess the potential role of AGT in Dacarbazine induced apoptosis a single
dose of Benzylguanine (60mg/kg) was administered to wild-type mice at time zero.
MSH2 +/+ mice were subsequently injected with 150mg/kg Dacarbazine at 0, 1, 6, 12,
24, 48, or 72 hours after Benzylguanine delivery. Six hours after each Dacarbazine
injection, levels of apoptosis were scored in the small intestine (Figure 3.5). Prior to
Benzylguanine delivery, Dacarbazine induced high levels of apoptosis with a mean of
over 60 apoptotic bodies per 50 half crypts. However, from 1 to 6 hours after
Benzylguanine injection, Dacarbazine was unable to induce apoptosis above baseline
rates. At 12 hours the apoptosis-inducing properties of Dacarbazine returned albeit at
a diminished level. Twenty-four hours after Benzylguanine delivery Dacarbazine was
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Figure 3.4
One hour following 60mg/kg i.p. Benzylguanine (BeG), cohorts of MSH2 +/+ and
MSH2 -/- mice were treated with Temozolomide (lOOmg/kg), or MNNG (50mg/kg),
or Cisplatin (lOmg/kg). Small intestines were harvested 6 hours following drug
treatment and apoptosis scored. Data is presented showing the percentage reduction
in observed apoptosis in the MSH2 -/- mice (open bars) relative to that in MSH2 +/+
mice (closed bars, standardised to 100%). Non-Benzylguanine treated controls are











Following a single dose of Benzylguanine (60mg/kg) at time zero, MSH2 +/+ mice
were injected with 150mg/kg Dacarbazine at 0, 1, 6, 12, 24, 48, or 72 hours after
Benzylgunaine delivery. Six hours after each Dacarbazine injection levels of apoptosis
were scored in the small intestine. Each point represents data from 3 mice. Error bars
represent sem.
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able to induce apoptosis with the same efficiency as before. Hence, Benzylguanine
administration reversibly inhibited the apoptosis-inducing action of Dacarbazine.
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Discussion
In the untransformed cells of the small intestine and colon MSH2 status did not affect
resting AGT levels. Loss of MSH2 which occurs in a proportion of RERf sporadic
tumours is therefore unlikely to alter cellular AGT levels per se. This may be of clinical
relevance since tumour cells which display high levels of AGT activity render
themselves resistant to methylating agents (Koc et al., 1996; Preuss et al., 1996). The
lower levels of AGT observed in the liver and lungs of MSH2 -/- mice suggest that
MSH2 may play a role in the regulation of AGT levels. However, this finding is
perhaps of limited significance as such a role for MSH2 would be predicted to lead to
an increased tumour sensitivity in these tissues, which has not been observed in MSH2
null mice.
Effective depletion of AGT activity was confirmed in tissue from the liver, colon and
small intestine with no detectable AGT activity occurring between 1 and 12 hours after
Benzylguanine administration. This confirms previous studies by (Liu et al., 1996c)
showing that Benzylguanine is active in vivo, and capable of depleting AGT activity in
the liver which is known to possess the highest levels of AGT activity (Pegg & Byers,
1992). In addition, Benzylguanine successfully depleted AGT from both the colon and
small intestine, creating a "window" of AGT depletion in which to study MSH2-
dependent apoptosis without any confounding effects of AGT.
No induction of apoptosis was associated with Benzylguanine treatment alone in
MSH2 +/+ or MSH2 -/- mice. This excluded the possibility that either Benzylguanine
itself or depletion of AGT could induce apoptosis in the murine small intestine. In the
absence of AGT activity Temozolomide, MNNG, Cisplatin, and y-irradiation all
induced apoptosis. The levels of apoptosis recorded were similar to the levels observed
in the presence of AGT. Thus, in wild-type mice AGT depletion neither reduced nor
augmented the prevalence of apoptosis in the intestine following a variety of DNA
damaging agents. Three possible explanations exist for this surprising result. First, it is
possible that AGT plays no role in MS7/2-dependent and -independent apoptosis in the
small intestine. This is unlikely since preincubation of colorectal cell lines with
Benzylguanine is known to potentiate the cytotoxicity of Temozolomoide (Wedge et
al., 1996). A second explanation stems from the possibility that Temozolomide
treatment ablates cellular AGT activity by depleting pools of unmethylated AGT, and
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therefore masking a potential role for AGT in apoptosis (Pegg & Byers, 1992; Lacal et
al., 1996). This explanation also seems unlikely given the levels of apoptosis were
similar in both Benzylguanine treated and untreated mice following a range of low
doses of Temozolomide. The most plausible explanation stems from the fact that the
murine small intestine possesses very low resting levels of AGT, and thus the predicted
increase in apoptosis following pre-treatment with Benzylguanine is too small to be
detected. Hence, in the presence and absence of Benzylguanine, the number of
methylated guanine residues is likely to be similar, and the number of cells possessing
levels of damage which are processed into lethal intermediates through MSH2, also
similar. This is the most satisfactory reason for the non-significant difference between
Benzylguanine and non-Benzylguanine treated wild-type mice, although it is impossible
to exclude the other possibilities discussed above.
Apoptosis scored in MSH2 +/+ and MSH2 -/- mice 6 hours following administration of
Temozolomide, MNNG, and Cisplatin and 7 hours after Benzylguanine, was again
observed to be dependent on MSH2 status, with a significant reduction observed in
MSH2 -/- mice (p<0.02 with Temozolomide and MNNG, Mann-Whitney U). The
degree of MSH2 dependency was comparable to non-Benzylguanine treated mice
demonstrating reproducibility in the absence of AGT. This result substantiates in vitro
data which demonstrate that mismatch repair status, overrides AGT status in
determining the apoptotic response of cells to Temozolomide (Liu et al., 1996b; Wedge
el ah, 1996).
What role if any does AGT play in small intestinal apoptosis? It is clear from the results
presented here that Benzylguanine administration blocks Dacarbazine-induced
apoptosis. This must be occurring either because AGT activity is required by
Dacarbazine to induce apoptosis, or because Benzylguanine is blocking the normal
metabolism of Dacarbazine. Dacarbazine is known to undergo oxidative N-
demethylation to its active compound 5-(3-methyltriazen-l-yl)imidazole-4-
carboxamide (MITC) (Newell et al., 1987; Dollery, 1991; D'lncalci, 1994). This
metabolic pathway occurs in hepatocytes through the action of cytochrome P450
enzymes (Meer et ah, 1986; Mudipalli et al., 1995). Two observations argue in favour
of the possibility that Benzylguanine is blocking the normal metabolism of
Dacarbazine. First, Temozolomide is able to induce apoptosis in the presence of AGT
depletion. Thus, the inhibitory action of Benzylguanine cannot be arising subsequent to
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Figure 3.6
Diagram of the metabolism of Dacarbazine (DITC) and Temozolomide to the active
compound 5-(3-methyltriazen-l-yl)imidazole-4-carboxamide (MITC). It is MITC
which is capable of methylating the O6 of guanine in DNA, creating O6-
methylguanine, the major pre-mutagenic lesion. DITC requires oxidative N-
demethylation by cytochrome P450 enzymes to form MITC, unlike Temozolomide
which reacts spontaneously with water to give MITC.
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the generation of MITC since it is also the active compound formed when
Temozolomide undergoes spontaneous chemical transformation (Stevens et al., 1987;
Denny et al., 1994) (Figure 3.6). Second, one of the major routes of metabolism of
Benzylguanine in mice involves oxidation to form fZ-Benzyl-S-oxoguanine (Dolan et
al., 1994) which occurs exclusively through the cytochrome P450 system (Nebert &
Weber, 1990). The possibility therefore arises that Benzylguanine metabolism may
competitively deplete cytochrome P450 activity.
Benzylguanine used at high doses of 60mg/kg appears capable of inhibiting the
demethylating ability of cytochrome P450 enzymes in the mouse liver. The
consequences of this novel finding are likely to be significant in view of the pivotal role
of P450 enzymes in the metabolism of drugs and carcinogens. Important drugs
metabolised by P450 enzymes include antibiotics (e.g. erythromycin),
immunosuppressants (e.g. cyclosporin), steroids (e.g. testosterone), cholesterol and
ethanol (Funae & Imaoka, 1993; Guengerich, 1992). Moreover, carcinogens such as
aflatoxin Bl, 2-aminoanthracene, and the mammary carcinogen fluoranthene-2,3-diol
are also known to be metabolised by hepatic P450 enzymes (Guengerich, 1992;
Shimada, et al., 1997).
There is increasing interest in the possible use of Benzylguanine clinically as an
adjuvant to alkylating agent chemotherapy to overcome tumour resistance mediated by
AGT and also to potentiate the cytotoxic effects of the chemotherapy (Wedge &
Newlands, 1996; Kurpad et a/., 1997). For a number of reasons the potential clinical
benefits of Benzylguanine may be overestimated. First, alkylating agents themselves are
capable of inactivating AGT activity by depleting cellular pools (Pegg & Byers, 1992).
Second, the addition of Benzylguanine to cells treated with MNNG or Temozolomide
is known to increase mutation rates and chromosome aberrations within cells, although
there is a proportional increase in apoptosis (Lukash et al., 1991; Bean et al., 1994;
Chinnasamy et al., 1997). Third, from the data presented in this thesis, it is clear that in
the murine small intestine AGT depletion does not elevate in vivo apoptotic levels at
six hours following methylating DNA damage. However, the possibility that a delayed
elevation in apoptosis in the absence of AGT was not excluded. In addition, the data is
this thesis indicate that Benzylguanine can alter the metabolism of drugs or
carcinogens, exemplified here by Dacarbazine, and may therefore be a cause of
unexpected adverse drug reactions if used clinically.
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Part IV
MSH2 and in vivo Mutation Frequency
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MSH2 and in vivo Mutation Frequency
Introduction
Deleterious genetic changes, known as mutations, are the basis of cancer (Bodmer et
al., 1994). Activating mutations in oncogenes or inactivating mutations in tumour
suppressor genes can contribute to the deregulation of cell turnover and progression
to a malignant state (Vogelstein & Kinzler, 1993). Mutations within cells can arise
through infidelity in the cellular DNA synthesis machinery, or defects in DNA repair
pathways or through environmental genotoxic insult (Kaufmann & Paules, 1996). The
DNA mismatch repair pathway, of which MSH2 is one component, combines a dual
function being essential for repairing mismatches and small DNA loops that arise
through errors in DNA replication and also for the cytotoxicity of mismatched
methylated guanine residues arising from alkylating carcinogens (Karran & Bignami,
1994). Absence ofMSH2 within normal cells may therefore facilitate the acquisition
of new mutations within key growth controlling genes, accelerating progression
through the multi-step process of cancer formation (Karran, 1996). Indeed, in vitro
studies demonstrating one hundred to six hundred-fold elevations in mutation rate at
the hypoxanthine guanine phosphoribosyltransferase (hprt) locus in colorectal cell
lines, deficient in mismatch repair, confirm the essential role of MSH2 in maintaining
DNA integrity (Bhattacharyya et al., 1994 & 1995; Eshelman et al., 1995; Branch et
al., 1995). Furthermore, studies of mutation rates in MSH2 -/- mice reveal five to
fifteen-fold elevations in the spontaneous mutation frequency (Andrew et al., 1997).
The role ofMSH2 in maintaining genomic stability within small intestinal stem cells in
vivo was investigated by determining the mutation frequency at the Dlb-1 locus
(Winton et al., 1988). The contribution of MSH2 in counteracting the mutagenic
effects of Temozolomide, MNNG, and Cisplatin was examined. The Dlb-1 assay
detects genetic change (including point mutations and deletions) at a single
polymorphic locus, Dlb-1, which determines a lectin binding site within mouse
intestinal epithelium. Two forms of the Dlb-1 allele exist. The Dlb-1 a allele specifies
binding of the lectin Dolichos biflorus agglutinin (DBA) to vascular epithelium while
the Dlb-1 b allele specifies binding to intestinal epithelium. Any inactivating mutation
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in the Dlb-1 b allele of Dlb-1 heterozygote mice (Dlb-1 a/b) renders that cell unable
to bind the lectin. Following stem cell proliferation and clonal expansion, an entire
clone of cells unable to bind the lectin is formed. Such clones are easily identified and
quantitated by staining wholemount preparations of the small intestine with a
peroxidase conjugate of DBA (Winton et al., 1988). These mutant clones of cells
migrating up the villus appear as white ribbons a brown-staining background (Figure
4.1). Therefore, mutation frequency may be expressed as the number of negative-
staining ribbons per ten thousand villi counted. Interbreeding MSH2 heterozygote
Dlb-1 a/a mice to MSH2 heterozygote Dlb-1 b/b mice generated cohorts of MSH2
+/+, MSH2 +/-, and MSH2 -/- mice which were also heterozygous (a/b) at the Dlb-1
locus. These mice were used to assess the mutation frequency of intestinal stem cells.
Results
Is there an elevated spontaneous mutation frequency in small intestinal stem cells of
MSH2-deficient mice?
The number of negative-staining clones per 10 000 villi was counted in thirteen week
old Dlb-1 a/b mice, four of which were MSH2 +/+, four MSH2 +/-, and four MSH2
-/- (Figure 4.2). Both untreated MSH2 wild-type and heterozygote mice demonstrated
low mutation frequencies (between 3 and 5 negative-staining ribbons per 10 000 villi)
similar to the spontaneous mutation rates of small intestinal cells recorded in previous
studies (Winton et al., 1988; Clarke et al., 1997). In contrast, MSH2 null mice
demonstrated spontaneous mutation rates 6-fold greater than either wild-type or
heterozygote mice (p<0.001, Mann-Whitney U).
What is the role of MSH2 in protecting against the mutagenic effects of different
doses of Temozolomide, MNNG and Cisplatin?
Ten week old cohorts of MSH2 +/+, MSH2 +/-, and MSH2 -/- Dlb-1 a/b mice were
injected i.p. with 0, 25, 50, and lOOmg/kg Temozolomide. Twenty-one days later the
number of negative-staining ribbons per 10 000 small intestinal villi was counted
(Figure 4.2). Low mutation frequencies were observed in both MSH2 wild-type and
heterozygote mice at all doses of Temozolomide which were not significantly different
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Figure 4.1
Small intestinal villus from a Dlb-1 a/b MSH2 -/- mouse stained with Dolichos





Mutation frequency in Dlb-1 a/b heterozygote mice, which also segregated for MSH2
status, following treatment with Temozolomide. Mice were injected i.p. with 0, 25,
50, and lOOmg/kg of Temozolomide and the number of negative-staining ribbons per
10 000 villi counted 21 days later. Each bar represents data from a minimum of three
mice and error bars correspond to the standard error of the mean. Wild-type, Dlb-1
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from untreated mice (p>0.1, Mann-Whitney U). In contrast, a significant MSH2-
dependent difference in mutation frequency was observed at all doses of
Temozolomide in MSH2 null homozygotes (p<0.02 for all doses, Mann-Whitney U).
Similar cohorts of mice were injected i.p. with 0, 10, 25, and 50mg/kg MNNG and
mutation frequency assessed 21 days later (Figure 4.3). At 10 mg/kg low mutation
frequencies were observed in both MSH2 wild-type and heterozygote mice. However,
doses of 25 and 50 mg/kg MNNG induced mutations at a frequency of between 50
and 150 ribbons per 10 000 villi. Comparing MSH2 +/- mice with MSH2 +/+ mice no
gene dosage effect was observed in the heterozygotes even at 50mg/kg. In MSH2 null
homozygotes all doses of MNNG induced high mutation frequencies with up to 400
negative-staining ribbons per 10 000 villi recorded at 50 mg/kg. At all doses of
MNNG MSH2-deficient mice showed elevated mutation rates above those observed
in wild-type and heterozygote controls. However, only 10 and 50 mg/kg of MNNG
were statistically significant (p<0.001, Mann-Whitney U).
Finally, Cisplatin was injected i.p. at 0, 0.5, 1, and 5mg/kg to cohorts of Dlb-1 a/b
mice which segregated for MSH2 status. The number of negative-staining ribbons was
counted 21 days post-injection (Figure 4.4). In MSH2 wild-type and heterozygote
mice Cisplatin was weakly mutagenic, with increasing doses of reagent increasing the
mutation frequency observed. Cisplatin was also mutagenic in MSH2 null homozygote
mice, although the absolute mutation frequency was low (up to 60 ribbons per 10 000
villi). At 5mg/kg Cisplatin a minor, but not statistically significant, degree of MSH2
dependency was detected, which was not present at lower doses.
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Figure 4.3
Mutation frequency in Dlb-1 a/b heterozygote mice, which also segregated for MSH2
status, following treatment with MNNG. Mice were injected i.p. with 0, 10, 25, and
50mg/kg of MNNG and the number of negative-staining ribbons per 10 000 villi
counted 21 days later. Each bar represents data from a minimum of three mice and
error bars correspond to the standard error of the mean. Wild-type, Dlb-1 a/b MSH2
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Figure 4.4
Mutation frequency in Dlb-1 a/b heterozygote mice, which also segregated for MSH2
status, following treatment with Cisplatin. Mice were injected i.p. with 0, 0.5, 1, and
5mg/kg of Cisplatin and the number of negative-staining ribbons per 10 000 villi
counted 21 days later. Each bar represents data from a minimum of three mice and
error bars correspond to the standard error of the mean. Wild-type, Dlb-1 a/b MSH2





To date only one study has documented the in vivo mutation rate in MST/2-deficient
mice (Andrew et al., 1997). Mice homozygous null for MSH2 and containing a
retrievable transgenic lacl reporter gene revealed 4.8, 11 and 15.2-fold elevations in
spontaneous mutation frequencies in tissue from the brain, small intestine and thymus
respectively, compared to wild-type controls (Andrew et al., 1997). However,
mutation rate studies using lamda shuttle vectors harbouring the lad gene are subject
to multiple confounding factors. First, the lad gene is heavily methylated and is not
expressed (Provost & Short, 1994). This is important since there is evidence to
suggest that actively transcribed genes are preferentially repaired (Bohr, 1991).
Second, insertions larger than 8kb are packaged ineffectively into phage particles
because of the size constraint on genomic DNA that a phage particle can
accommodate. Furthermore, large deletions may involve the reporting construct itself.
Thus, chromosomal rearrangements, gene amplifications or large deletions or
insertions may not be detected by this method of analysis (Nishino et al., 1995).
Third, the integration of the transgene may disrupt a cellular gene that is involved in
DNA repair, DNA replication, or the metabolic processes that contribute to DNA
damage (Gossen et al., 1991). Lastly, de novo mutations may arise in Escherichia coli
during analysis. Alternatively, Escherichia coli may repair lesions in the transgene that
were present in the mouse DNA. The Dlb-1 assay is not subject to these potential
sources of error and therefore constitutes a more accurate and meaningful
determination of the in vivo mutation frequency in MSH2 -/- mice.
In both MSH2 wild-type and heterozygote mice Temozolomide, at the doses used,
was unable to increase the mutation frequency at the Dlb-1 locus. In contrast, in an
MSH2 null environment the mutation frequency was elevated at all doses with MSH2
deficiency resulting in a 13.8-fold increase at lOOmg/kg Temozolomide compared to
wild-type controls. These results confirm MSH2 as a key defence mechanism against
alkylating-type DNA damage. Variations in f/'-alkylguanine-DNA-alkyltransferse
(AGT) activity are unlikely to modulate these observations since AGT levels in the
murine small intestine are independent ofMSH2 status (see Part III of this thesis) and
high doses of alkylating agent deplete functional AGT activity (Pegg & Byers, 1992).
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MNNG proved to be a more potent mutagen than Temozolomide, generating over
400 negatively staining ribbons per 10 000 villi at the doses studied. However, in
contrast to Temozolomide, MNNG was mutagenic in wild-type and heterozygote
animals at doses of 25 and 50mg/kg. Thus, at these doses the combined protective
mechanisms of MSH2 and AGT were inadequate to prevent mutations.
Notwithstanding such differences between MNNG and Temozolomide, the MNNG
mutation data clearly demonstrate again that MSH2 forms a critical defence
mechanism against the mutagenic properties of alkylating agents. Indeed, at the
highest dose of MNNG (50mg/kg), MSH2 deficiency resulted in a 5.0-fold elevation
in mutation frequency at the Dlb-1 locus compared to MSH2 +/+ mice.
Cisplatin was found to be weakly mutagenic in small intestinal cells with increasing
doses of Cisplatin resulting in increased mutation frequencies in MSH2 wild-type and
heterozygote mice. However, in contrast to alkylating agents, MSH2 deficiency led to
an small increase in mutation frequency only at the highest dose of Cisplatin (5mg/kg).
Moreover, the MSH2 dependency of this response was less than that of either
Temozolomide or MNNG, with only a 1.7-fold elevation in mutation frequency being
observed at 5mg/kg Cisplatin. The most direct conclusions from these results are
twofold. First, Cisplatin is weakly mutagenic in small intestinal cells. Second, MSH2
plays little or no role in counteracting Cisplatin induced mutagenic DNA damage,
except perhaps at high doses when MSH2 deficiency may become significant. Given
that MSH2 is known to bind 1,2 diguanyl Cisplatin cross-links these findings are
surprising. This may be explained by the observation that platinated DNA is not per se
a good substrate for the MSH2 repair complex, but on the other hand Cisplatin
adducts occurring on mismatched base pairs bind MSH2 effectively (Yamada et al.,
1997). Alternatively, it may be that within small intestinal cells 1,2 diguanyl adducts
do not mediate the mutagenic effects of Cisplatin or that stem cells with Cisplatin-
DNA lesions are effectively removed by apoptosis signalled by other pathways, and
do not contribute to the mutation frequency.
The mutation data presented in this chapter correlates positively with the apoptotic
response of small intestinal cells to the same reagents, although this should be
interpreted with caution given that data is available for only three genotoxic agents.
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However, a marked MSH2 dependency exists for both the reduction in apoptosis and
the increase in mutation frequency observed after treatment with Temozolomide. In
contrast, the apoptotic and mutagenic effects of Cisplatin show little MSH2
dependency with the responses following MNNG exposure being intermediate in
nature (Figure 4.5). Taken together these findings provide supportive evidence for the
hypothesis that apoptosis is involved in the deletion of crypt cells bearing DNA
damage and preventing the propagation of mutant daughter cell clones. Furthermore,
these data suggest that the specificity of MSH2 for the DNA lesion may determine
both the mutation frequency and the apoptotic response in MSH2 null mice.
The significance of this mutation data to tumourigenesis is threefold. First, cells which
lose MSH2 function develop spontaneous mutation frequencies of approximately six¬
fold higher than normal cells. Second, intestinal cells that lack MSH2, such as those
that may occur in the intestines of HNPCC patients, are particularly susceptible to the
mutagenic effects of alkylating agents. Indeed, intestinal epithelia may be exposed to
an alkylating agent rich environment in the form of bile acid conjugates which have
undergone N-nitrosation, or components of the normal diet capable of DNA
methylation (Shuker et al., 1981; Hall et al., 1991; Bingham et al., 1996). Thus, loss
of the DNA mismatch repair pathway in such an environment may result in mutation
frequencies several fold higher than those due to MMR deficiency alone. Third,
treatment of RER tumours with methylating agents such as Temozolomide may
actually increase the mutation frequency within the tumour cells themselves and
consequently accelerate, rather than retard, tumour progression.
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Figure 4.5
A positive correlation (r=0.99) exists between the increase in mutation frequency at
the Dlb-1 locus due to MSH2 deficiency and the reduction in apoptosis due to MSH2
deficiency following treatment with Temozolomide, MNNG, and Cisplatin. The
reduction in apoptosis resulting from MSH2 deficiency was calculated from the ratio
of the areas under the graphs ofMSH2 wild-type and MSH2 null mice in Figures 1.3
A, B, and D. The contribution of MSH2 deficiency to the mutation frequency was
calculated by determining the ratio of the increase mutation frequency (taking into
account background mutation rates) in MSH2 null mice compared to wild-type mice
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MSH2, p53 and Tumourigenesis
Introduction
Cancer is the endpoint of an evolutionary-like process whereby normal cells are
transformed into malignant cells by the cumulative acquisition of genetic changes
which confer proliferative, invasive, and metastatic properties upon the cell
(Vogelstein & Kinzler, 1993). This process can be rapidly accelerated by the loss of
systems that safeguard genomic stability resulting in an increased rate of mutagenesis
and chromosomal rearrangements (Hartwell, 1992; Kolodner, 1995).
Acquisition of genomic instability in colorectal cancers involves two separate
pathways (Schlegel et ah, 1995; Cottu et al., 1996; Lengauer et al., 1997). First, in a
small proportion of colorectal cancers, defects in components of the DNA mismatch
repair pathway, for example MSH2 deficiency, lead to microsatellite instability - an
indication of a "mutator phenotype" at the nucleotide sequence level (Liu et ah,
1995). In addition, loss of MSH2 has been shown to suppress homologous
recombination between diverged DNA sequences and confer resistance to methylating
agents (de Wind et ah, 1995). Furthermore, the mismatch repair system is essential
for a functional G2 cell cycle checkpoint (Hawn et ah, 1995). Thus, MSH2 is a key
component in the maintenance of cellular genomic stability. Second, in the majority of
colorectal cancers no evidence of microsatellite instability can be identified. However,
genomic instability in terms of major changes to chromosomes occurs leading to
aneuploidy - abnormal chromosome number (Reichmann et ah, 1981). Defects inp53
are thought to contribute to this gross form of instability for three reasons. First, in
colorectal cancer alterations in p53 precede and are correlated with the divergence of
aneuploid sub-clones (Carder et ah, 1993). Second, normal non-permisssive cells
become permissive for DNA amplification when p53 is lost (Livingstone et ah, 1992;
Yin et ah, 1992). Third, p53 null cells display elevated mutation rates following y-
irradiation induced DNA strand breaks (Clarke et ah, 1997). In addition to an
important role in maintaining chromosome stability, p53 may also be involved in
maintaining stability at the nucleotide level since the C-terminal domain ofp53 binds
DNA mismatches (Lee et ah, 1995). Thus p53, like MSH2, plays a pivotal role in
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maintaining DNA integrity and preventing malignancy. The controls governing which
pathway of instability predominates in colorectal cancer are unknown. Furthermore,
no data exists on the interaction between mismatch repair-mediated genomic
instability and /?53-mediated genomic instability.
To study the interactions of these two genes at the level of the organism, mice doubly
null for MSH2 and p53 were generated. Since both MSH2 null and p53 null mice
develop tumours spontaneously, any acceleration in tumourigenesis or shift in tumour
phenotype observed in double null mice would provide evidence of a positive
interaction between MSH2 and p53 deficiency. Furthermore, by examining tumours
arising in double null mice the contribution of each type of genomic instability to
tumourigenesis, either MS7/2-mediated or /?53-mediated, could be addressed. First,
the effects ofMSH2 nullizygosity upon p53 null-associated female embryonic lethality
were investigated.
Results
Are mutant MSH2 /p53 inter-crossed mice viable?
The F1 progeny from mating MSH2 -/- mice to p53 -/- mice were all viable and
developed normally. Crossing the F1 progeny {MSH2 +/- p53 +/-) together generated
a large cohort of mice which segregated for both MSH2 and p53, and produced mice
with all genotypic combinations. Only mice with the following genotype were studied:
MSH2 -/- p53 +/+, MSH2 +/+ p53 -/-, MSH2 -/- p53 +/-, MSH2 +/- p53 -/-, and
MSH2 -/- p53 -/-. All of these groups of mice appeared phenotypically normal with no
profound aberrant effects on early viability being observed. Both males and females in
all five genotype groups were fertile beyond eight weeks of age.
Does MSH2 status affect p53 null-associatedfemale embryonic lethality?
In cohorts of MSH2 +/+, MSH2 +/-, and MSH2 -/- mice (on a wild-type p53
background) the number of male and female mice was in accordance with the
expected 1:1 Mendelian ratio (Table 5.1). However, in allp53 -/- mice, irrespective of




p53 +/+ p53 -/-
MSH2 +/+ 262/254 (-2%) 26/12 (-37%)
MSH2 +/- 118/94 (-11%) 52/21 (-42%)
MSH2 -/- 166/177 (+3%) 61/22 (-47%)
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the number of live-born female mice was observed (Table 5.1). Thus, MSH2 status
does not affect /?55-associated female embryonic lethality.
Can MSH2 and p53 deficiency co-operate to accelerate tnmourigenesis in murine
tissues?
Cohorts of MSH2 +/+ p53 +/+, MSH2 +/- p53 +/+, MSH2 -/- p53 +/+, MSH2 +/+
p53 -/-, MSH2 +/- p53 -/-, MSH2 -/- p53 +/-, and MSH2 -/- p53 -/- mice were studied
to investigate survival and tumourigenesis. Colonies were monitored for up to 240
days. Mice were killed when they appeared visibly ill and their age was calculated in
days. Kaplan-Meier survival plots were generated for all genotypes of MSH2 / p53
inter-crossed mice (Figure 5.1). Survival data for MSH2 +/+ p53 +/- mice was
generated from historical controls (Purdie et al, 1994). Wild-type mice, together with
both MSH2 and p53 heterozygotes, were viable and healthy up to 240 days. However,
all mutant MSH2 / p53 inter-crossed mice succumbed earlier to tumours. The median
age of survival for each colony was as follows: MSH2 -/- p53 +/+ 142 days; MSH2
+/+ p53 -/- 121 days; MSH2 +/-p53 -/- 106 days; MSH2 -/-p53 +/- 99 days; MSH2
-/- p53 -/- 65 days. Thus, MSH2 -I- p53 -/- mice developed tumours and died
significantly earlier than either MSH2 -/- or p53 -/- mice alone (p< 0.0006, log rank
test), demonstrating co-operativity between the two genes. MSH2 heterozygosity on a
p53 null background did not significantly alter survival from p53 nullizygosity alone
(p>0.09, log rank test). In contrast, MSH2 nullizygosity in p53 heterozygote mice
resulted in a dramatic reduction in survival compared with p53 heterozygote mice
possessing intact MSH2 (p<0.00001, log rank test). Thus, MSH2 deficiency
accelerated tumourigenesis in p53 heterozygote mice, although p53 deficiency did not
accelerate tumourigenesis in MSH2 heterozygote mice.
What is the incidence and spectrum of tumours that develop in mutant MSH2 /p53
inter-crossed mice?
Full autopsies were performed on mice which were identified as sick. All findings
were recorded and any gross pathology, including tumours noted. H&E sections of
the tissues taken at autopsy were examined by a histopathologist. No developmental
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abnormalities were noted in any group of mice although a variety of tumours
including thymic and extra-thymic lymphomas, leiomyosarcomas, and adenomas and
adenocarcinomas from the small and large intestine were found (Figure 5.2 & 5.3).
The incidence of the various tumours identified in mutant MSH2 /p53 inter-crossed
mice is summarised in Table 5.2. MSH2 null mice all succumbed to lymphoma with
approximately half of these being extra-thymic in origin. In addition, adenomas and
adenocarcinomas were found in 15% and 25% of the animals' small and large
intestines respectively. The majority (88%) of p53 null mice died from lymphoma
although a small proportion (12%) died from either leiomyosarcoma or osteosarcoma.
No gastrointestinal tract lesions were identified in p53 null mice. Ninety-five percent
of MSH2 -/- p53 +/- mice died of lymphoma with equal proportions of thymic and
extra-thymic origins being observed. 11% of these mice had identifiable
gastrointestinal tract neoplasms. MSH2 +/- p53 -/- mice were similar to p53 -/- mice
in that they developed lymphoma (67%) or sarcoma (33%). However, in contrast to
MSH2 +/+ p53 -/- mice all of the lymphomas in MSH2 +/- p53 -/- were extra-thymic
in origin and both sarcomas were located in the caecal wall. MSH2 -/- p53 -/- all
succumbed to thymic lymphomas. No adenomas or adenocarcinomas were identified
in their intestines.
Does APCAf'" heterozygosity alter the nature and incidence of tumours arising in
mice doubly nullfor MSH2 andp532
Min (APC +/Mi") mice were crossed to MSH2 -/- p53 +/- mice generating a colony of
APC +/Mm MSH2 -/- p53 -/- mice (Table 5.2). These mice developed thymic
lymphoma at a similar age to MSH2 -/- p53 -/- mice (p>0.2, log rank test). However,
50% of these mice also developed acinar pancreatic adenomas and adenocarinomas
analogous to those found in APC +/Mm p53 -/- mice by Clarke et al. (1995). In
addition, all of the A PC +/Mm MSH2 -/- p53 -/- mice developed adenomas and
adenocarcinomas in both their small and large bowels. The adenomas and
adenocarcinomas were similar to those found in Min mice alone (Moser et al., 1990)
or in APC +/Mm MSH2 -/- mice (Reitmair et al., 1996b). Thus, APtf4'" heterozygosity
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Figure 5.2
(A) H&E stained section of a thymic lymphoma arising in a MSH2 -/- p53 -/- mouse.
Note the abundance of apoptotic bodies present (arrowed) and their contribution to
the classical "starry sky" appearance often seen in lymphomas. (X250)
(B) H&E stained section of a leiomyosarcoma arising in the caecum of a MSH2 +/-
p53 -/- mouse. An arrow depicts an island of normal colonic epithelium surrounded by
tumour tissue. (X250)
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Figure 5.3
(A) H&E stained section of mouse colon with an early benign adenoma. The genotype
of the mouse was APC +lhi'n MSH2 -/- p53 -/-. Note the cellular hyperplasia,
pleomorphism and hyperchromatism evident within the neoplastic glands. (X250)
(B) H&E stained section of a colonic adenocarcinoma removed from a 7 month old





Autopsy results and median age of death in days of cohorts of mutant MSH2 / p53
inter-crossed mice. Lymphomas were subdivided into those of thymic origin and those
in which an extra-thymic site was primarily involved. Sarcomas encompassed both
leiomyosarcomas and osteosarcomas while all pancreatic neoplasms identified were
acinar in origin. Neoplasia in the small intestine and colon referred to the presence of
both benign adenomas and malignant adenocarcinomas arising within epithelial cells.
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did not significantly alter the survival of MSH2 -/- p52 -/- mice but did alter the
tumour spectrum substantially.
What is the immunophenotype of the thymic lymphomas that arise within mutant
MSH2 / p53 inter-crossed mice? Does genotype influence the immunophenotype of
lymphomas?
Thymic lymphomas from sick mice of genotypes MSH2 -/- p53 +/+, MSH2 +/+ p53
-/-, MSH2 -/- p53 +/-, and MSH2 -/- p53 -/- of known age were characterised by
immunophenotyping studies. Antibodies specific to CD2, CD4, CD8, CD24, CD45,
Thy-1, macrophages (F4-80), B cells (anti-mouse IgG) and the interleukin-2 receptor
(IL-2R) were used to assess the cell surface markers present on lymphoma cells by
flow cytometry. All of the tumours examined were of T-cell origin. B-cell and
macrophage markers failed to stain tumour cells above background levels. Levels of
IL-2R positivity were low with less than 10% of cells staining positive with no
relationship to genotype being observed (data not shown). However, tumours from
MSH2 -/- p53 -/- mice retained high levels of expression of CD2, CD4, CD8, CD24,
CD45 and Thy-1 molecules (Figure 5.4 & 5.5). In contrast, tumours from MSH2 -/-
p53 +/- mice, which succumbed at a later stage, displayed lower levels of all the cell
surface molecules examined (p<0.01 for all markers, Mann-Whitney U). Single null
mice (MSH2 -/- or p53 -/-) displayed variable patterns of expression of cell surface
markers, with some tumours retaining molecules and others losing them. No
consistent pattern of antibody staining could be assigned to tumours arising in MSH2
null or p53 null mice.
What effect does MSH2 deficiency have on the remaining wild-type copy ofp53 in
tumours arising in MSH2 nullp53 heterozygote mice?
DNA from thymic lymphomas arising in MSH2 -/- p53 +/- mice was amplified by a
/?53-specific PCR reaction (Figure 5.6). No loss of heterozygosity (LOH) was
observed in any of the nine thymic lymphomas examined, thus demonstrating that no
gross chromosomal deletion of the remaining wild-type p53 allele had occurred. In
addition, total RNA was extracted from three of these tumours and reverse
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Figure 5.4
Immunophenotype of thymic lymphomas arising in mutant MSH2 / p52 mice. Data
presented as a scatter plot of the percentage of tumour cells staining positive for
cluster of differentiation (CD) antigens CD2, CD4, and CD8 against the age of the
mouse's death in days. Open circle symbols, MSH2 -/- p53 +/+; closed square
symbols, MSH2 -/- p53 +/-; open triangular symbols, MSH2 -/- p53 crosses,
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Immunophenotype of thymic lymphomas arising in mutant MSH2 / p53 mice. Data
presented as a scatter plot of the percentage of tumour cells staining positive for
membrane antigens CD24, CD45, and Thy-1 against the age of the mouse's death in
days. Open circle symbols, MSH2 -/- p53 +/+; closed square symbols, MSH2 -/- p53

























































UV-transilluminated, ethidium bromide stained 2% TBE agarose gel showing
retention of the wild-type p53 allele in lymphomas from MSH2 -/- p53 +/- mice by
specific PCR reaction. The arrow denotes the retained wild-type p53 allele. L DNA
ladder molecular weight marker; C PCR negative control with only the p53 targeted
event detected; 1-9 Tumour DNA from 9 separate thymic lymphomas arising in 9
different MSH2 -/- p53 +/- mice.
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LC 1 23456789
transcribed into cDNA. Exons 5-9 of the wild-type p53 allele were amplified by PCR
and sequenced (Table 5.3). A single G—»A transition was observed at codon 234 in
one of the tumours and was predicted to give an amino acid change from methionine
to isoleucine. In the remaining two tumours no mutation was identified in exons 5-9
ofp53.
How do mutant MSH2 and p53 interact in the development of aneuploidy in
tumours?
The DNA content of cells from thymic lymphomas arising in MSH2 -/- p53 +/+,
MSH2 +/+ p53 -/-, MSH2 -/- p53 +/- and MSH2 -/- p53 -/- mice was analysed by flow
cytometry. The DNA content of the tumours was classified as either diploid or as
aneuploid if an additional Gi or G2 peak with a different DNA index was present
(Figure 5.7). All lymphomas fromMSH2 -/- p53 +/+, MSH2 -/-p53 +/- and MSH2 -/-
p53 -/- mice displayed a diploid karyotype (Table 5.4). In contrast, 2 out of 7 (29%)
of the lymphomas from MSH2 +/+ p53 -/- mice showed evidence of aneuploidy.
What is the nature of the genomic instability, assessed by comparative genomic
hybridisation (CGH), in tumours from MSH2 null, p53 null, MSH2 mdl p53
heterozygote, and doubly null mice?
DNA from thymic lymphomas arising in MSH2 -/- p53 +/+, MSH2 +/+ p53 -/-, MSH2
-/- p53 +/- and MSH2 -/- p53 -/- mice was analysed by CGH. CGH was performed on
a minimum of five metaphase spreads per tumour and an average green/red profile
generated for each chromosome. A green / red ratio outside the limits of 1.125 or
0.875 was scored as an increase or decrease in DNA content for a single
chromosome. MSH2 -/- p53 +/+, MSH2 -/- p53 +/- and MSH2 -/- p53 -/- tumours
displayed stable genomes with few gains in the DNA content of individual
chromosomes being identified (Table 5.5). In contrast, MSH2 +/+ p53 -/- tumours
showed a considerable number of amplified regions of DNA within their
chromosomes (Table 5.5). However, all the tumours examined, irrespective of
genotype, showed few areas of gross chromosomal deletions.
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Table 5.3
Mutational analysis of exons 5-9 of the wild-type p53 allele in thymic lymphomas
arising in three different MSH2 -/- p53 +/- mice. An in frame G —>A transition was
identified at codon 234 which was predicted to give an amino acid change from





\MSH2 -/- p53 +/-]
Mutations in exons 5-9 wild-
type p53 allele
Predicted amino acid change
Thymic lymphoma 1 G —» A [codon 234] Methionine —> Isoleucine
Thymic lymphoma 2 none detected N/A
Thymic lymphoma 3 none detected N/A
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Figure 5.7
Examples of diploid (A) and aneuploid (B) flow cytometric analyses of DNA content
of murine thymic lymphomas. The arrow denotes an aneuploid Gi peak arising in a






Flow cytometric analyses of thymic lymphomas from MSH2 -/- p53 +/+, MSH2 +/+
p53 MSH2 -/- p53 +/-, MSH2 -/- p53 -/- mice. Tumours were classified as either
diploid or as aneuploid. Aneuploidy was identified by the presence of an additional Gi
or G2 peak within the cellular DNA content.
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Table 5.4
Thymic Lymphoma Total number
of tumours
Diploid Aneuploid
MSH2 -/- 7 7 0
p53 -/- 7 5 2
MSH2 -/- p53 +/- 7 7 0
MSH2 -/- p53 -/- 7 7 0
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Table 5.5
Comparative genomic hybridisation (CGH) analyses of murine thymic lymphomas
arising in mice of varying MSH2 and p53 genotypes. Regions of amplified DNA (G
for gained) or areas of deleted DNA (L for loss) are shown for all of the 19 mouse
autosomes. CGH was performed on a minimum of five metaphase spreads per tumour
and an average green/red profile generated for each chromosome. An increased or
decreased DNA content of a single chromosome corresponded to a green/red ratio
outside of 1.125 or 0.875 respectively which was equivalent to gain or loss of one
whole chromosome in 25% of diploid cells.
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Table 5.5
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All genotypic combinations of mutant MSH2 / p53 inter-crossed mice, including
MSH2 -/- p53 -/- mice were viable with a normal phenotype initially. The successful
generation ofMSH2 -/- p53 -/- mice was not surprising since both MSH2 -/- mice and
p53 -/- mice alone are viable. Data from the cohort of mutant MSH2 / p53 inter¬
crossed mice showed that the male / female ratio in MSH2 -/- p53 -/- was similar to
the ratio observed in MSH2 +/+ p53 -/- mice. Hence, p53 nullizygosity, irrespective of
MSH2 status, conferred a reduction (40%) in the number of live born female mice.
This level of female embryonic lethality was identical to previous reports on the
relative deficiency of female mice from /?53-associated exencephaly and subsequent
anencephaly observed in outbred crosses (Armstrong et al., 1995). Thus, the
combined effects of both MSH2 and p53 working in parallel did not affect viability or
alter embryonic development significantly from p53 -/- mice alone, demonstrating that
dual MSH2 and p53 deficiency does not adversely affect embryogenesis. Furthermore,
male and female MSH2 -/- p53 -/- mice were used in breeding pairs confirming that
these mice are fertile, and proving that successful gametogenesis can occur in a
background of combined p53 and MSH2 deficiency.
Previous studies have demonstrated that male mice bearing targeted inactivations of
both p53 and MSH2 are viable, but succumb rapidly to lymphoma earlier than either
p53 or MSH2 singly null mice (Cranston et al., 1997). This study reported that all
female mice nullizygous for both p53 and MSH2 underwent developmental arrest at
9.5 days and died in utero (Cranston et al., 1997). In addition, Cranston et al. did not
report a significant reduction in the number of female p53 -I- mice from Mendelian
ratios, although the authors state that this was probably due to their small cohort size
(only seven p53 -/- mice). Similarly, male mice generated in this thesis which were
null for both p53 and MSH2 were also viable and succumbed to lymphoma at an
equally early age, with a median age of death of 65 days. However, the results
presented in this thesis differ substantially from the findings of Cranston et al. in the
successful generation of 22 adult female mice nullizygous for both p53 and MSH2
which possess an identical phenotype to their male counterparts. Four possible
explanations may account for the discrepancy between the data presented in this thesis
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and the work of Cranston et al. (1997). First, the discrepancy may have resulted from
different levels of environmental insult. However, as the colony used in this thesis was
not maintained under barrier conditions this therefore seems unlikely. Second, the
difference observed may have arisen through the use of different genetic backgrounds.
Indeed, previous studies have documented the strain dependency of yoJ-related
anencephaly (Armstrong et al., 1995). Against this possibility is the fact that both
groups of mice were generated from outbred crosses derived from a mixture of mouse
strains and previous analysis has shown that different out-crossed strains possess
similar levels of /?53-related embryonic death (Armstrong el al., 1995). Although the
parental strains used to generate the mutant MSH2 / p52 inter-crossed cohort in this
thesis differed from those used by Cranston et al., both have been well characterised
previously (Donehower et al., 1992; Clarke et al., 1993; Reitmair et al., 1995; de
Wind et al., 1995). In fact the mice used in this thesis segregated for 129/Ola, Balb-c
and SWR genomes whereas the mice studied by Cranston et al. contained genomes
derived from 129/Ola, 129/Sv, and C57BL/6J strains. More importantly, the single
null MSH2 and p53 parental strains studied in this thesis possessed very similar
reported phenotypes to those used by Cranston et al. (Donehower et al., 1992; Purdie
et al., 1994; Reitmair et al., 1995; de Wind et al., 1995). Notwithstanding these
observations it still remains possible that the female MST/2-related death observed by
Cranston et al. was in fact strain dependent. Third, it is possible that the female
embryonic lethality observed by Cranston et al. arose as a consequence of a second
mutation which was co-segregating with one or other of the targeted alleles. The
likelihood of such a linked mutation may perhaps have been increased if either of
these cohorts had been derived from Embryonic Stem cells engineered over an
extended period in vitro to carry multiple mutations, but this was not the case with
either of the cohorts (Donehower et al., 1992; Clarke et al., 1993, de Wind et al.,
1995; Reitmair et al., 1995). Finally, it is possible that the targeted events differed in
some way either at the targeted locus itself or by the influence of the targeted locus
upon neighbouring genes. Although it is impossible to confirm or refute any of the
above explanations, it is clear from the data presented in this thesis that, at the very
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least, the reported female embryonic lethality associated with MSH2 and p53
deficiency is not fully penetrant.
Wild-type and MSH2 heterozygote mice were all viable up to the age of 240 days
with no animals developing tumours, confirming previous studies by de Wind et al.,
(1995) and Reitmair et al., (1995 & 1996a). The median age of death of MSH2 -/-
mice in this thesis was 142 days which is in accordance with the published data of
Reitmair et al. (1996a) of approximately 150 days. p53 null mice used in this thesis
succumbed at an average age of 121 days which is similar to that reported previously
by Purdie et al. (1994). Combined nullizygosity for MSH2 and p53 decreased survival
to a median of 65 days which is in concordance with the MSH2 -/- p53 -/- mice of
Cranston et al. (1997) which had a median age of death of 73 days. Notwithstanding
any minor differences in survival, both the Kaplan-Meier plots presented here and
published by Cranston et al. are in complete agreement with MSH2 -/- p53 -/- mice
succumbing first, followed by p53 -/- mice and finally MSH2 -/- mice displaying
longer survival. Thus, despite differences in strain and targeting events between the
various knockout mice, the survival data is closely similar.
In addition to possessing similar survival curves, the cohorts of mice in this thesis also
developed the same spectrum of tumours reported by previous studies. All of the
MSH2 -/- mice developed lymphomas of T-cell origin together with adenomas and
adenocarcinomas of both the small and large intestine, which were found only in mice
over 140 days old. These findings are identical to those of de Wind et al., (1995) and
Reitmair et al. (1995 & 1996a) and confirm that both MSH2 deficient strains possess
a closely similar phenotype despite different targeting events and different genetic
backgrounds. Furthermore, one of the MSH2 -/- mice outwith the cohort group
developed a keratoacanthoma analogous to the Muir-Torre syndrome as previously
reported by Reitmair et al., (1996a). p53 null mice in this thesis developed the same
range of tumours as reported by Purdie et al., (1994), although the incidence of
sarcoma reported in this thesis may be an underestimate since the carcasses were not
X-rayed to detected osteosarcomas. The tumour spectrum observed in MSH2 -/- p53
-/- mice was similar to that of Cranston et al. although no sarcomas, histiocytomas, or
intestinal adenomas were observed in this cohort. Indeed, only thymic T-cell
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lymphomas were observed. The most likely explanation to account for the lack of any
additional tumours in the MSH2 -/- p53 -/- mice in this thesis is that these tumours are
rare and did not manifest themselves in the relatively small cohort examined (20
mice). Alternatively, subtle differences between the two stains of mice, highlighted
above, may account for the lack of additional tumours.
Ape1"'"" heterozygosity on a MSH2 -/- p53 -/- background did not alter survival in
mice, but modified the spectrum of tumours to include intestinal and pancreatic
adenomas and adenocarcinomas. The development of intestinal tumours was not
surprising since APC +/Mm MSH2 -/- mice develop numerous such lesions (Reitmair et
al., 1996b). The accelerated development of adenomas seen in APC +/Min MSH2 -/-
mice is thought to result from somatic mutation of the wild-type APC allele by MSH2-
deficiency induced point mutation (Reitmair et al., 1996b). It is unlikely that the
appearance of intestinal lesions in APC +/A/,n MSH2 -/- p53 -/- mice is the result of
p53 nullizygosity since APC +/M'" p53 -/- do not show increased intestinal malignancy
when compared to Min mice alone (Clarke et al., 1995). Notwithstanding the above
observations, it is remains possible that MSH2 and p53 can co-operate to accelerate
gastrointestinal tract tumourigenesis, since no quantitative analysis of adenoma
number was performed in the APC +/Mm MSH2 -/- p53 -/- mice. The development of
pancreatic adenomas and carcinomas mAPC +/Mm MSH2 -/- p53 -/- mice is consistent
with previous studies on APC +/Mm p53 -/- mice by Clarke et al. (1995) which
demonstrated that p53 nullizygosity on a Min background leads to the appearance of
pancreatic tumours. The APC +/Mm MSH2 -/- p53 -I- mice generated therefore
demonstrated no new tumour phenotype and instead displayed a combination of
tumours already seen in MSH2 -I- p53 -/- mice, APC +/M'n MSH2 -/- mice, and APC
+lM'" p53 -/- mice. Thus, APCMm heterozygosity does not accelerate lymphoma
development or decrease survival in MSH2 -I- p53 -/- mice.
MSH2 +/- p53 -/- mice succumbed at similar age to p53 -/- mice alone. Thus, MSH2
heterozygosity on a p53 null background does not accelerate tumourigenesis. This is
not surprising since MSH2 +/- cells do not show microsatellite instability, and are
proficient in DNA mismatch repair (de Wind et al, 1995; Kolodner, 1995). However,
it is possible that the remaining wild-type MSH2 allele may act as a target for p53
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null-induced mutation since deficiency of p53 has been shown to cause genomic
instability (Bouffler et al., 1995; Levine, 1997), DNA amplification (Yin et al., 1992)
and elevations of in vivo mutation rates following high doses of DNA damage (Clarke
et al., 1997). Since MSH2 +/- p53 -/- mice survived to a similar age as MSH2 +/+ p53
-/- mice it suggests that this scenario does not occur, with p53 null-induced tumours
being unable to capitalise upon a single copy ofMSH2. This can be reconciled by the
observation that p53 deficiency is only mutagenic at high levels of DNA damage,
whereas in untreated intestinal cells p53 deficiency does not alter the in vivo mutation
rate (Clarke et al., 1997). However, it is interesting to note that MSH2 heterozygosity
appears to alter the site of lymphoma development (i.e. outwith the thymus) and
influences the site of sarcoma development. The reasons for these anomalies are
unclear at present, although a shift in tumour phenotype was also observed in APC
+lMmp53 -/- mice (Clarke et al., 1995).
In sharp contrast, MSH2 -/- p53 +/- mice succumbed at a significantly earlier age than
MSH2 null mice alone, with a median survival of only 99 days versus 142 days. Thus,
p53 heterozygosity accelerated tumour development in a MSH2 -/- background, but
did not alter the tumour spectrum. MSH2 -/- cells show microsatellite instablility and
possess elevated mutation rates (de Wind et al., 1995, Eshelman et al., 1995; Part IV
of this thesis). One possible explanation for the acceleration in tumourigenesis seen in
these mice is that MSH2 deficiency may predispose the cell to covert a p53 +/- cell to
a p53 null cell by point mutation of the remaining wild-type allele. This alone would
explain an increased incidence in tumour development. In the nine thymic lymphomas
examined, loss of the remaining untargeted p53 allele was excluded by PCR.
Sequencing data from three of these tumours demonstrated a single point mutation in
only one of the tumours. However, this mutation was a G—»A transition and occurred
at codon 234 in the mouse. Such a base transition is characteristic ofMSH2 deficiency
(Andrew et al., 1997) and its site is located in a known mutational hot spot of p53
occurring in the sequence-specific DNA-binding domain of the p53 protein
(Vogelstein & Kinzler, 1992; Levine, 1997). The absence of mutation in exons 5-9 of
p53 in the other two tumours sequenced does not exclude the possibility that MSH2
deficiency induced point mutations in other exons of p53 or the promoter of p53.
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Notwithstanding the above observations, these results demonstrate that in one tumour
at least, mutant MSH2 can positively interact with heterozygous p53 to enhance
tumour development. However, a second explanation for the accelerated
tumourigenesis seen in MSH2 -/- p53 +/- mice arises from the possibility that p53
heterozygosity itself predisposes to tumourigenesis. Analysis of the status of the wild-
type p53 allele in tumours taken from p53 +/- mice demonstrated that over 50% of
the tumours examined retained an intact, and functional wild-type p53 allele (L.
Donehower, personal communication). This indicates that a mere reduction in p53
levels is sufficient to cause tumours. Hence, accelerated tumour development
observed in MSH2 -/- p53 +/- mice may result from mutation of the remaining p53
allele or may simply reflect a reduction in p53 protein levels in the heterozygous state.
Which of these pathways predominate is unclear at present although this issue could
be resolved by yeast analyses aimed at determining p53 function (Flaman et al., 1995).
These results, together with the data of Reitmair et al. (1996b), demonstrate that
MSH2 deficiency combined with heterozygosity at another tumour suppressor locus
(APC) leads to accelerated tumour development. The most likely mechanism for this
phenomenon is that MSH2 deficiency results in greater susceptibility to point
mutations in the remaining wild-type allele and effectively converts that cell to a
double null genotype.
Immunophenotyping of the thymic lymphomas arising in mutant MSH2 / p53 inter¬
crossed mice demonstrated a T-cell origin. Both singly null MSH2 and p53 mice are
also known to develop T-cell lymphomas (Purdie et al., 1994; de Wind et al., 1995;
Reitmair et al., 1995). Tumours from MSH2 -/- p53 -/- mice retained surface
molecules CD2, CD4, CD8, CD24, CD45 and Thy-1. In contrast, lymphoma cells
from MSH2 -/- p53 +/- mice displayed lower levels of all the cell surface markers
examined. Why should this occur? One possible explanation for this is that the cell of
origin of the lymphomas is different between genotypes, with MSH2 -/- p53 -/- driven
tumourigenesis affecting an earlier lineage of T-cell progenitors which express more
surface markers (Godfrey & Zlotnik, 1993). Alternatively, differences in cell surface
molecule expression may result from differences in genotype alone, although this is
unlikely since neither MSH2 nor p53 is known to affect T-cell marker expression.
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Furthermore, thymocyte development is normal in MSH2 null mice (Reitmair el al.,
1995). Therefore, doubly null T-cells, since they possess two genome destabilising
pathways may undergo malignant conversion earlier in T-cell ontogenesis with
progenitor T-cells expressing high levels of cell surface proteins which the tumours
retain. In contrast, MSH2 -/- p53 +/- T-cells become malignant later in the life of a
mouse when T-cells are at a later stage of differentiation and are characterised by
fewer surface markers (Godfrey & Zlotnik, 1993). Inconsistent patterns of antigen
expression were observed in MSH2 -/- and p53 -/- tumours, and are in accordance
with the previous findings of Reitmair et al. (1995) and Purdie et al. (1994). Both of
the p53 -I- and the MSH2 -/- tumours were observed in mice significantly older than
either MSH2 -/- p53 -/- or MSH2 -/- p53 +/- mice. Thus, the inconsistent pattern of
expression seen in single null mice may reflect malignant conversion in T-cells after
lineage commitment has occurred when the patterns of marker expression are
different between different T-cell types.
Aneuploidy occurs frequently in colorectal and other cancers (Heim & Mitelman,
1987) and is often associated with a poor prognosis (Shackney et al., 1989).
Colorectal cancers without microsatellite instability demonstrate defects in
chromosome segregation, which result in gains or losses in excess of one whole
chromosome per hundred chromosomes replicated (Lengauer et al., 1997). This form
of karyotypic instability leads to the development of aneuploidy (Schlegel et al., 1995;
Lengauer et al., 1997) which is positively correlated withp53 mutation (Carder et al.,
1993). Furthermore, there is an inverse correlation between RER+ status and p53
mutation in colorectal cancer cell lines (Cottu et al., 1996). Colorectal cancers
therefore appear to exhibit two distinct forms of genomic instability, one through loss
of MMR and the other through loss ofp53. This thesis has already demonstrated that
although distinct, these two pathways can co-operate at the level of the organism to
accelerate tumourigenesis. Analysis ofMSH2 -/- tumour cells by both flow cytometry
and CGH demonstrated no aneuploidy or chromosomal instability. In contrast, 29%
of tumours from p53 null mice were aneuploid with CGH analysis showing evidence
of chromosomal instability in the form of DNA amplification. MSH2 -/- p53 -/-
tumours displayed a diploid karyotype with no evidence of any chromosomal
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instability being demonstrated either by flow cytometry or CGH. The absence of any
form of gross chromosomal instability in these tumours is surprising given that p53
deficiency exists. Three possible explanations may account for the absence of p53-
associated genetic changes in these tumours despite the known co-operativity
between the two genes. First, deficiency ofp53 may contribute to tumourigenesis by
reducing genome stability at a nucleotide level, in a similar manner to MSH2
deficiency. This is unlikely since the frequency of microsatellite instability in tumours
from MSH2 -/- p53 -/- mice is not significantly different from that of MSH2 -/- mice
(Cranston et al., 1997). Second, tumours arising in MSH2 -/- p53 -/- mice develop
rapidly, perhaps before gross chromosomal changes occur or if they do occur are
undetectable by flow cytometry or CGH. Third, p53 deficiency may enhance
lymphomagenesis, not through DNA instability, but through inhibition of apoptosis
(Clarke et ah, 1993; Lowe et ah, 1993a).
The significance of these findings to malignancy is that combined MSH2 and p53
deficiency accelerates tumour development. In the case of colorectal cancer such a
scenario rarely occurs (Cottu et al., 1996). However, examples of combined
microsatellite and chromosomal instability do exist (Lengauer et al., 1997), showing
that these pathways are not mutually exclusive. Indeed, the results presented in this
thesis demonstrate that despite combined MSH2 and p53 deficiency only an MSH2-
deficiency type pattern of genomic instability is detectable in tumour cells. In addition,
the survival data from MSH2 -/- p53 +/- mice highlights the risk of being
heterozygous at a tumour suppressor loci in the presence ofMSH2 deficiency.
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SUMMARY
I MSH2 plays a major role in coupling DNA mismatch type lesions to
apoptosis efficiently in the murine small intestine. MSH2 is specific for DNA
mismatch type lesions with cells requiring only one copy of MSH2 for induction
of apoptosis. MSH2 status does not alter the target population of cells exposed to
methylating agents or Cisplatin.
II p53 is required for the "immediate" apoptotic response in small intestinal
cells following methylating agents or Cisplatin. Delayed />55-independent
apoptosis is observed following Temozolomide, and is entirely MS7/2-dependent.
Both the crypt position and the morphology of apoptosis is altered in delayed
/?5J-independent apoptosis.
III MSH2 status does not alter resting AGT levels within cells. AGT
appeared to play no significant role in MVi/2-dependent apoptosis following
DNA damage in the murine small intestine. Benzylguanine, a competitive
inhibitor of AGT, prevents the metabolic activation of Dacarbazine probably
through the inhibition of cytochrome P450 enzymes.
IV Absence of MSH2 increases the spontaneous mutation frequency at the
Dlb-1 locus within cells of the murine small intestine six-fold. An MSH2-
dependent increase in mutation frequency is observed following exposure to
MNNG and Temozolomide. In contrast, MSH2 plays little or no role in the
defence against Cisplatin-induced mutations.
V MSH2 and p53 can co-operate to accelerate tumourigenesis in the mouse.
Examination of tumours from MSH2 -/- p53 -/- mice demonstrate that only
MSH2-type instability can be detected. This suggests that p53 may accelerate





Generation and maintenance of mouse colonies
All mice were maintained under non-barrier conditions, and given a standard diet and
water ad libitum. From a single MSH2 +/- male mouse (de Wind et al., 1995) a large
cohort ofMSH2 +/+, MSH2 +/-, and MSH2 -/- mice were generated on an outbred
background segregating for a variety of genomes including 129/Ola, Balb-c, and
SWR.
Interbreeding MSH2 -/- mice to p53 -I- mice (Clarke et al., 1993) a colony of animals
was generated which segregated for both mutant alleles. The background of this
outbred colony included 129/Ola, Balb-c, and SWR genomes. Mice of the following
genotypes were used for study or breeding: MSH2 -/- p53 +/+, MSH2 +/+ p53 -/-,
MSH2 -/- p53 +/-, MSH2 +/-P53 -/-, MSH2 -l-p53 -/-.
By interbreeding MSH2 -I- p53 +/- to Min mice (Moser et al., 1990, Su et al., 1992)
a cohort of mice with the genotype APC +/Mw MSH2 -/- p53 -/- were generated.
By mating MSH2 -/- male mice to wild-type C57BL/6J female mice the F1 progeny
from this mating were designated Colony "A". Thus, Colony A mice were MSH2 +/-,
homozygous for the Dlb-1 a allele (Dlb-1 a/a), and 50% C57BL/6J (Winton et al.,
1988). A second cohort of mice was generated by mating MSH2 +/- mice to wild-
type C57BL/6J which were homozygous for the Dlb-1 b allele (Dlb-1 b/b) (Winton et
al., 1988). MSH2 +/- progeny from this mating were back-crossed to C57BL/6J Dlb-
1 b/b mice. Four subsequent back-crosses to C57BL/6J Dlb-1 b/b mice were
performed, maintaining MSH2 +/- status. Dlb-1 status of the mice was determined by
staining formalin fixed tail biopsies with Dolichos biflorus agglutinin peroxidase
(Winton et al., 1988). MSH2 +/- Dlb-1 b/b progeny from the final matings were
designated Colony "B".
By crossing Colony "A" mice to Colony "B" mice the F1 progeny generated were all
heterozygous at the Dlb-I locus {Dlb-1 a/b) and also either MSH2 +/+, or MSH2 +/-,
or MSH2 -/-. These mice were used for the in vivo mutation frequency experiments.
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DNA extraction from mouse tails
DNA was extracted from mouse tail biopsies using Puregene (Gentra Systems) as per
protocol. Alternatively, DNA was extracted as follows: tail biopsies were digested
overnight at 37°C in 500pl Phenol Lysis Buffer and 25pl Proteinase K (20mg/ml).
500pl of Phenol was added, mixed, and microfuged at 13 000 rpm for 2 minutes. The
top layer was removed, an equal volume of Phenol/Chloroform added, mixed, and
microfuged as before. The upper layer was then removed, an equal volume of
Chloroform/Iso-amyl alcohol added, mixed, and microfuged as before. The top layer
was again removed, and DNA precipitated with 250pl of 7.5M Ammonium Acetate
and 3.75mls absolute ethanol. DNA was removed by pipette, air-dried for 10 minutes
and resuspended in 500pl TE buffer. Samples which required only MSH2 status were
boiled in 500pl of MSH2-PCR Lysis Buffer for 15 minutes.
Genotyping mice by PCR
MSH2
As a large number of samples required genotyping for MSH2 status, and the only
method available was Southern Blotting (de Wind et al., 1995), a specific PCR assay
for MSH2 status was designed. Studying the mouse genomic MSH2 targeting event in
de Wind et al. (1995) a three primer approach was identified with a sense primer in
intron 11 of mouse MSH2 (Primer 1), and two antisense primers, the first in the polyA
tail of the targeting cassette to detect the targeted allele (Primer 2), and a second
antisense primer in exon 12 downstream of the targeting event, to detect the wild-type
allele (Primer 3). In order to design Primer 1 approximately 100 base pairs of intron
11 (the sequence of which was unpublished) was sequenced using Primer 3 and
plasmid pHA224 (H. te Riele, unpublished) which contains a 12.5kb BamHl fragment
of mouse genomic MSH2. Sequencing was carried out using the dideoxy chain
termination method using Sequenase 2.0 (Amersham) used as per manufacturer's
protocol with 2pmoles Primer 3 and 5pg of plasmid pHA224 (lpl of Manganese
buffer was added at the extension step). 2.5pi of reaction mixture was boiled for 5
minutes, loaded on to a 6% acrylamide gel, and run at 75 watts until the bromophenol
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blue migrated to the bottom of the gel. The gel was fixed in 12% methanol / 10%
acetic acid solution for 15 minutes and attached to Whatmann 3MM filter paper. The
gel was covered with cling film, vacuum dried at 80°C for 1 hour then exposed to X-
ray film (Biomax MR, Kodak) overnight at 4°C in a hypercassette. The film was
developed using a Hyperprocessor (Amersham). The sequence identified was used to
design Primer 1. A PCR reaction specific to MSH2 was optimised and generated a
164 base pair product for the wild-type allele and 194 base pair product for the
targeted event (Figure A).
The protocol was as follows: to a 50pl PCR reaction containing 5pl PCR Buffer,
2.5jlx1 1%WI, 2.5pl each primer (lOpmoles per pi), lpl dNTP (40mM), 2pl MgCl2
(50mM), 30pl DDW and lpl Taq (1.25U) (all components GibcoBrl), lpl (lOOng) of
template DNA was added. The reaction mix was overlain with 50pl paraffin oil.
Reaction conditions were 94°C 5min, 60°C 2min, 72°C 2min (XI); 94°C lmin, 60°C 2
min, 72°C 2 min (X30); 94°C lmin, 60°C 2min, 72°C lOmin (XI) (OmniGene,





p53 status was determined by specific PCR reaction (Malcomson et al., 1997). 2pl
(200ng) of template DNA was added to a 50pl PCR reaction containing 5pi PCR
Buffer, 2.5pl 1%WI, 2.5pl each primer (lOpmoles per pi), lpl dNTP (40mM), 2pl
MgCl2 (50mM), 2pl DMSO, 27pl DDW and lpl Taq (1.25U) (all components
GibcoBrl). The reaction mix was overlain with 50pl paraffin oil. Reaction conditions
were 94°C 2min (XI); 94°C lmin, 62°C lmin, 72°C 1 min (X30); 72°C lOmin (XI)
(OmniGene, Flybaid). 20pl of product was analysed on a 2% TBE agarose gel.
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Figure A
UV-transilluminated, ethidium bromide stained 4% TBE agarose gel, showing MSH2
specific PCR. L lkb ladder molecular weight marker (sizes of bands in base pairs are
arrowed); WT MSH2 +/+, 164 base pair product; HET MSH2 +/-, 164 and 194 base
pair products; HOM MSH2 194 base pair product.
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Min PCR
Min status of mice was determined by the PCR reaction and Hindlll digestion
described by Luongo et al. (1994). 2pl (200ng) of template DNA was added to a 50pl
PCR reaction containing 5 pi PCR Buffer, 2.5pi each primer (lOpmoles per pi), lpl
dNTP (40mM), 2.5 pi MgCl2 (50mM), 33.5pl DDW and lpl Taq (1.25U) (all
components GibcoBrl). The reaction mix was overlain with 50pl paraffin oil. Reaction
conditions were 94°C 2min (XI); 94°C lmin, 60°C lmin, 72°C 1 min (X30); 72°C
lOmin (XI) (OmniGene, Hybaid). 16pl of product digested with Hindlll (GibcoBrl)
for 1 hour at 37 °C. Digested product was analysed on a 4% TBE agarose gel.
Reagent administration / irradiation of mice
Ten week old mice were given intraperitoneal (i.p.) injections of various doses of
MNNG, Temozolomide, Cisplatin, or Benzylguanine. Doses of reagent was mg per
kg body weight of mouse (mg/kg). The injection volume for all reagents was from 0.2
to 0.5ml per mouse. All drugs, except Cisplatin (David Bull Laboratories), were
prepared fresh and first dissolved in DMSO (10% of the final volume) and made to a
final concentration with PBS (Temozolomide & Benzylguanine) or corn oil (MNNG).
Mice were exposed to y-irradiation using a 137Caesium source at 0.27 Gray per minute
for 15 minutes, so that each mouse received a total dose of 4 Gray.
Quantitation of apoptosis
All experiments were initiated at the same time of day (10 00 hours a.m.) in order to
control for the effects of diurnal changes in susceptibility to apoptosis, since a clear
circadian rhythm has been shown to exist for the induction of apoptosis in the murine
small intestine (Potten, 1990). At a specified time point following reagent injection or
irradiation, a minimum of three mice were killed, their small intestines removed. A ten
cm section proximal to the caecum was flushed with water, opened longitudinally and
fixed overnight in methocarn. Samples were rolled into "swiss-rolls" and stored in
70% ethanol prior to staining. Haematoxylin and eosin (H&E) stained sections were
made and apoptosis scored through the use of the Highly Optimised Microscopic
164
Environment (HOME) (Brugal et al., 1992; Clarke et al., 1994). Each slide was
assigned an arbitrary reference number by a separate individual and data was therefore
collected blind. A random section of slide displaying crypts cut in longitudinal plane
was identified. Consecutive crypts were marked using the HOME microscope such
that the same crypt was not counted twice. Running mean values were determined
prior to counting and demonstrated that an accurate mean for murine apoptotic bodies
was generated beyond approximately 40 half crypts. A minimum of fifty half-crypts
were scored per animal. To address the possibility of intra-observer error sample
slides were scored on three separate occasions. Counts obtained this way did not
markedly differ from each other (the degree of error was always below 15%). To
remove the possibility of inter-observer error sample slides were rechecked by an
independent observer. This process was facilitated by the use of the HOME
microscope as individual assessments of cell status were verified by the second
observer. Some inter-experimental variation in the level of apoptosis was observed.
Such differences in the prevalence of apoptosis between comparable experiments may
arise from a number of possible variables: 1) small differences in mouse size 2) small
inaccuracies in drug delivery 3) differences in sex ratio between experiments 4)
difference in histological preparation of samples which may have influenced the ease
of identification of apoptosis. Taken together these differences may well account for
the observed inter-experimental variation, however, within individual experiments
these factors were more closely controlled as sex ratios and the age of mice closely
matched. In addition, the small intestines from each experiment were stained and
sectioned as a single batch.
To determine the crypt position of cells undergoing apoptosis, cumulative counts of
one hundred apoptotic bodies were performed on histological sections. In slides to be
counted a random section of longitudinally cut crypts were identified and one hundred
apoptotic bodies were counted in consecutive crypts progressing in the same direction
around the "swiss-roll". Each apoptosis was assigned a crypt position from 1 to 22 as
previously described (Potten, 1990; Clarke et al., 1994), with position one at the base
and twenty-two at the apex. Mean data was generated from three slides.
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fZ-AIkylguanine-DNA-alkyltransferase (AGT) assay
Mice were sacrificed, tissues of interest removed, snap frozen in liquid nitrogen, and
stored at -70°C until assayed as described previously (Rafferty et al., 1996).
Dlb-1 mutation assay
Ten week old Dlb-1 a/b heterozygote mice generated from crossing Colony "A" to
Colony "B" were injected i.p. with a single dose of MNNG, or Temozolomide, or
Cisplatin. 21 days later the mice were killed, their small intestines removed, and
flushed with water. Whole mount preparations of 15 cm of the intestine were stained
with Dolichos biflorus agglutinin (DBA) peroxidase (Winton et al., 1988). Villus
ribbons not staining with the DBA-peroxidase conjugate were scored using Kyowa
Stereo 200M microscope and the results presented as number of mutations per 10 000
villi.
Mouse cohort survival and tumour incidence
Cohorts of mice with altered genotypes were maintained as separate colonies. The
genotype and number of mice in each cohort were as follows: MSH2 +/+ 29 mice,
MSH2 +/- 30 mice, MSH2 -/- 28 mice, MSH2 +/+ p53 -/- 88 mice, MSH2 +/- p53 -/-
23 mice, MSH2 -/- p53 +/- 44 mice, MSH2 -/- p53 -/- 20 mice, A PC +/Mm MSH2 -/-
p53 -/- 8 mice. For each mouse, a date of birth and date of death was recorded. Mice
which were sick or moribund, were sacrificed, their age recorded, and a full autopsy
performed. All organs, including any tumour, were fixed in 4% buffered formaldehyde
and H&E histological sections made. Small intestine and colon were removed, flushed
with water, and fixed overnight in methocarn. Flistological sections of gut were made
as described previously (Clarke et al., 1994) and scored for adenomas and
adenocarcinomas. Samples of tumour tissue were stored at -70°C for RNA extraction
and Flow Cytometry. DNA was extracted from small pieces (3mm x 3mm) of tumour
by digestion in 5ml Phenol Lysis Buffer and 150pl of Proteinase K (20mg/ml) for
48hours at 55°C. DNA was prepared from 500pl of sample by the Phenol/Chloroform
method and resuspended in 500pl TE.
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Sequencing of wild-type p53 allele in MSH2 -/- p53 +/- mice
Total RNA was extracted from tumour tissue (5mm x 5mm) using 1ml Trizol
(GibcoBrl), and aliquotted at a concentration of lmg/ml in RNase-free DDW. lpl of
RNA was reverse transcribed into cDNA using oligo(dT)i5 primers and Expand
Reverse Transcriptase (Boehringer Mannheim) as per protocol. PCR primers 33A and
2IB (Ozbun et al., 1993) were used to amplify a 686 base pair fragment of p53
cDNA which included exons 5-9. A lOOp.1 PCR reaction containing 250ng of primers
33A and 21B, 0.5pl cDNA template and 5U Pfu DNA polymerase (Stratagene) was
performed using the thermocycling profile detailed in Ozbun et al. (1993). An aliquot
(10p.l) of each product was digested with Hinfl (Boehringer Mannheim) to verify that
amplification was from mRNA and not mouse p53 pseudogene DNA. For each
tumour cDNA three separate PCR reactions were performed. Each sample (90p.l) was
purified using Wizard PCR Preps DNA Purification System (Promega) prior to
cloning. lOOng of purified PCR product was cloned into pCR-Script SK+ vector
(Stratagene) as per manufacturer's protocol, lp.1 of ligation mixture was used to
transform Epicurian Coli XL2-blue Ultracompetent Cells (Stratagene) and a
blue/white selection screen performed. White transformants were grown in 5ml of
LB-Ampicillin for 8 hours. 1ml of each culture was used to inoculate lOOmls of LB-
Ampicillin. Cultures were grown overnight at 37°C in an orbital shaker. Plasmid DNA
was extracted using a Plasmid Maxi Kit (Qiagen). 5gg of plasmid DNA was
sequenced using a Fluorescent Automated DNA Sequencer (Licor). The p53 cDNA
insert was sequenced from both directions using T3 and T7 primers. Thus, exons 5-9
ofp53 in each tumour were amplified by PCR and sequenced by three separate and
identical reactions. p53 sequence data from each tumour was compared to that of
published wild-type p53 sequence (Arai et al., 1986) using DNA alignment software
available through Human Genome Mapping Project.
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Table 1
Table summarising the Primary and Secondary Antibodies used in the
immunophenotyping of the murine lymphomas. For each antibody details of the




Primary Antibody Origin Source Dilution
Anti-CD2 rat Pharmingen 1:100
Anti-CD45 rat Pharmingen 1:100
Anti-CD24 rat Pharmingen 1:100
Anti-IL2R rat Pharmingen 1:100
F4-80 rat ATCC 1:10
Anti-CD4 rat ECACC 1:10
Anti-CD8 rat ECACC 1:10
Anti-Thy-1 rat ECACC 1:10
Anti-mouse IgG mouse ECACC 1:10
Secondary Antibody
Anti-rat IgG (FITC) Rabbit Sigma 1:100
Anti-mouse IgG (FITC) Rabbit Sigma 1:100
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DNA flow cytometry
DNA content of tumours was analysed by a modified Vindelov method (Vindelov et
al., 1983). Tumour tissue (5mm x 5mm) was forced through a 100pm sieve together
with 500pl of Citrate Buffer to generate a single cell suspension. To lOOpl of Citrate
Buffer/Cell mixture, 450pl of Solution A was added and incubated for 10 minutes.
325pl of Solution B was then added for 10 minutes. Finally, 250pl of Solution C was
added and the sample incubated on ice for a further 10 minutes. DNA content was
analysed on a EPICS XL Flow Cytometer (Coulter) using Multicycle Software
(Coulter).
Immunophenotyping of tumours
Fresh tumour tissue in PBS (GibcoBrl) was forced through a 100pm sieve and spun at
1800 rpm for 10 minutes. Cells were resuspended in 1ml Freezing Medium and frozen
at -70°C overnight before transfer to liquid nitrogen. Prior to analysis samples were
defrosted and lymphocytes isolated using Lympholyte M (Cedarlane Laboratories) as
per protocol. Lymphocytes were resuspended in Flow Buffer to a concentration of 3
xl07/ml. lOOpl of cells were added to each well in a 96 well plate. The plate was spun
at 800 rpm for 3 minutes and the supernatant removed. 25pl aliquots of Primary
Antibody was added at various concentrations (Table 1) and incubated on ice for 1
hour. Cells were washed in 200pl of Flow Buffer, spun for 3 minutes at 800 rpm and
supernatant removed. 25pi of the appropriate Secondary Antibody as added and
incubated on ice for 1 hour (Table 1). 200pl of Flow Buffer was added, spun for 3
minutes at 800 rpm and supernatant removed. Cells were resuspended in 200pl of
Flow Buffer before analysis on the EPICS XL Flow Cytometer (Coulter) using XL2
Software (Coulter).
Non-commercial antibodies were isolated from the supernatants of Hybridoma Cell
Lines obtained from European Collection of Animal Cell Cultures (ECACC) or
American Type Culture Collection (ATCC). Antibodies were purified using protein G
columns (Sigma) as per manufacturer's instructions.
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Comparative genomic hybridisation
[Performed by Lucy Curtis]
Normal metaphases for comparative genomic hybridisation (CGH) were obtained
from cultured E14 mouse Embryonic Stem cells, which were originally derived from a
129/Ola cross (Hooper et a/., 1987). Cells were grown in CM5-5 medium in 75cm2
flasks. Metaphase spreads were prepared by standard protocols.
Comparative genomic hybridisation was carried out using the modified method of
Kallioniemi et al. (1993), with the substitution of 20pl mouse Cot-1 DNA for human.
Analysis of hybridisations was carried out using the Apple Macintosh based
quantitative image analysis software (MacProbe, Perceptive Scientific Instruments).
Karyotyping was performed manually. CGH analysis was carried out on a minimum of
five metaphase spreads per tumour. Green/red ratios were scored and an average
profile generated for each chromosome. Green/red cut-off points of 0.875 and 1.125
were chosen for scoring copy number changes which were equivalent to loss or gain
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No female embryonic lethality
in mice nullizygous for Msh2 and p53
Recently, it has been reported thatmale mice bearing targeted inactiv -
tions of both p53 and Msh2 are viable, but
rapidly succumb to lymphoma earlier than
either p53 or Msh2 single mutants. In con¬
trast, it was reported that all female mice
lacking p53 and Msh2 underwent develop¬
mental arrest at 9.5 days and died in utero].
The published study did not report a sig¬
nificant reduction in the number of female
P53'1' animals, although the authors state
that this is probably due to their small
cohort size. We have also generated male
mice lacking p53 and Msh2 which are
viable and succumb to lymphoma at a sim¬
ilarly early age (t'/: is 65 days). However, our
results differ from the data of Cranston et
al. in that we have successfully generated 22
adult female mice nullizygous for both p53
and Msh2. The parental strains used to gen¬
erate our cohort differ from those used by
Cranston et al., but both have been well
characterized previously2'3. Importantly,
the single mutant Msh2 and p53 parental
strains used in our cohort possess very sim¬
ilar reported phenotypes to those used by
Cranston et al.2~5. Data from our cohort
show the male to female ratio in Msh2~l~
P53'1' mice is similar to the ratio observed
in Msh2+I+ p53mice (Table 1). Thus, in
our cohort Msh2 plays no detectable role
in female development with the reduction
in female mice in our Msh2~l~ p53~'~ cohort
from expected Mendelian ratios being
accounted for by p53-associated exen-
cephaly and subsequent anencephaly6. We
observed an identical phenotype for
female Msh2~!~ P53'1' mice as for their male
counterparts, dying from lymphoma at a
similar age. We have used male Msh2 '
p53~' mice in successful breeding pairs,
confirming that these mice are fertile.
Table 1 • Male to female ratio in live born mice
p53*'* p53~'~
Msh2+I+ male/female 262/254 (-2%) 26/12 (-37%)
Msh2+'~ 118/94 (-11%) 52/21 (-42%)
Msh2^~ 166/177 (+3%) 61/22 (-47%)
Sex ratio of mice for each genotype group together with the percentage deviation from the expected 1:1
male to female ratio shown in brackets. The observed reduction in female mice doubly null for Msh2 and
p53 is not significantly different from that related to p53 deficiency alone (x2 test). In this data set
homozygosity for lack of p53, irrespective of Msh2 status, confers a significant reduction in the number of
female progeny (p< 0.01, %2 test).
We suggest four possible explanations for
the difference between our own data and
the work of Cranston et al. First, the dis¬
crepancy may result from different levels of
environmental insult. However, our colony
is not maintained under barrier conditions
and we therefore consider this unlikely.
Second, this difference may arise through
the use of different genetic backgrounds.
Indeed, we have previously documented the
strain dependency of p53-related anen¬
cephaly6. Against this possibility argues the
fact that both groups of mice were gener¬
ated from outbred crosses derived from a
mixture of mouse strains (our animals seg¬
regate for 129/Ola, Balb-c and SWR
genomes) and further, that our previous
analysis showed different outcrossed strains
to possess similar levels of p53-related
embryonic death6. Notwithstanding these
observations, it remains possible that the
observed Ms/i2-related death is strain
dependent, and we are currently carrying
out appropriate backcrosses to address this
point. Third, it is possible that the pheno¬
type observed by Cranston et al. is arising as
a consequence of a second mutation which
is linked to one or other of the targeted alle¬
les. The likelihood of such a linked muta¬
tion would perhaps be increased if either of
these cohorts had been derived from ES
cells engineered over an extended period in
vitro to carry multiple mutations, but this
was not the case'-11. Finally, it is possible
that the targetted events differ in some way,
either at the targetted locus itself or by the
influence of the targeted locus upon neigh¬
bouring genes. Although we cannot at pre¬
sent confirm or refute any of the above
explanations, it is clear from our data that,
at the very least, the reported female
embryonic lethality associated with Msh2
and p53 deficiency is not fully penetrant.
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